var title_f19_9_19600="Palpation subscapular bursa";
var content_f19_9_19600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Palpation of the subscapular bursa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The subscapular bursa can be palpated at the junction of the supeior-medial anlge of the scapula and the closest underlying rib.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19600=[""].join("\n");
var outline_f19_9_19600=null;
var title_f19_9_19601="Plexiform neurofibroma in a child with NF1";
var content_f19_9_19601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plexiform neurofibroma in a child with neurofibromatosis type 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 416px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical picture of a child with plexiform neurofibroma of the thigh in the distribution of the femoral nerve. This patient was subsequently operated on.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Canavese F, Krajbich JI. Resection of plexiform neurofibromas in children with neurofibromatosis type 1. J Pediatr Orthop 2011; 31:303. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19601=[""].join("\n");
var outline_f19_9_19601=null;
var title_f19_9_19602="Patient information: Jet lag (The Basics)";
var content_f19_9_19602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86224\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?13/48/14091\">",
"         Taking melatonin to prevent jet lag",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/59/21426\">",
"         Patient information: Constipation in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/4/38978\">",
"         Patient information: Daytime sleepiness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/58/22434\">",
"         Patient information: Insomnia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/16/2306\">",
"         Patient information: Insomnia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/24/28035\">",
"         Patient information: Insomnia treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Jet lag (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H93838206\">",
"      <span class=\"h1\">",
"       What is jet lag?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Jet lag is a condition that causes sleep problems, tiredness, and other symptoms. It happens in people who fly across several time zones. The more time zones a person crosses, the more likely he or she is to get jet lag.",
"     </p>",
"     <p>",
"      Jet lag gets better on its own as a person adjusts to the new time zone. But this can take several days. The farther from home a person is, the longer it takes to get over jet lag.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93838221\">",
"      <span class=\"h1\">",
"       What are the symptoms of jet lag?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sleep problems, such as problems falling or staying asleep",
"       </li>",
"       <li>",
"        Feeling tired or sleepy in the daytime",
"       </li>",
"       <li>",
"        Having trouble thinking, concentrating, or doing normal activities",
"       </li>",
"       <li>",
"        Stomach problems, such as constipation",
"       </li>",
"       <li>",
"        Feeling sick or having less energy than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93838236\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you think you had jet lag in the past, talk to your doctor or nurse before going on a long airline flight. He or she can help you figure out ways to avoid jet lag.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93838251\">",
"      <span class=\"h1\">",
"       How can I prevent jet lag?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Here are a few things you can try:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stay awake and sleep at certain times. This can help your body adjust to the new time zone. For example, you can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Stay up until it&rsquo;s dark if you fly west &ndash; Only go to sleep when it gets dark. If you go sightseeing, try to do it during the day.",
"       </li>",
"       <li>",
"        Avoid bright morning light if you fly east &ndash; Go outside as much as possible in the afternoon. If you go sightseeing outdoors, try to do it in the afternoon until your body adjusts to the new time zone.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eat meals at mealtime in the new time zone &ndash; For example, if you normally eat lunch at noon, eat at noon in the new time zone (not noon at home).",
"       </li>",
"       <li>",
"        Get some exercise, but not right before you are supposed to go to sleep.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93838266\">",
"      <span class=\"h1\">",
"       Can supplements or medicines help with jet lag?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. A supplement called &ldquo;melatonin&rdquo; can help with sleep problems from jet lag. Melatonin&nbsp;is a hormone that is naturally made by a gland in the brain. Taking extra melatonin can help your body adjust to a new time zone. You can buy melatonin pills in a store or pharmacy without a prescription. The usual dose is 2 or 3 milligrams after dark each night, about half an hour before you want to go to sleep.",
"     </p>",
"     <p>",
"      If you want to try melatonin, tell your doctor or nurse. He or she can tell you if it is safe for you. If you take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      (brand names: Coumadin&reg;, Jantoven&reg;) or medicine to help with epilepsy, melatonin might not be safe for you. Tell your doctor or nurse about all medicines and supplements you take, including over-the-counter medicines.",
"     </p>",
"     <p>",
"      The right way to take melatonin depends on whether you are traveling east or west (",
"      <a class=\"graphic graphic_table graphicRef86167 \" href=\"UTD.htm?13/48/14091\">",
"       table 1",
"      </a>",
"      ). You can take melatonin for up to 4 nights in the new time zone. After that, you are not likely to need it.",
"     </p>",
"     <p>",
"      Only adults should take melatonin. Doctors don&rsquo;t know if it helps with jet lag in children. Avoid drinking alcohol while you are taking melatonin.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93838298\">",
"      <span class=\"h1\">",
"       Does melatonin cause side effects?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have side effects from melatonin. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling sleepy in the daytime",
"       </li>",
"       <li>",
"        Dizziness or confusion",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Loss of appetite, nausea, and other stomach problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      But these side effects are very similar to jet lag. So doctors are not sure if they are really side effects of melatonin or just jet lag symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H93838315\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=see_link\">",
"       Patient information: Constipation in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       Patient information: Daytime sleepiness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=see_link\">",
"       Patient information: Insomnia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"       Patient information: Insomnia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"       Patient information: Insomnia treatments (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/9/19602?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86224 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19602=[""].join("\n");
var outline_f19_9_19602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838206\">",
"      What is jet lag?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838221\">",
"      What are the symptoms of jet lag?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838236\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838251\">",
"      How can I prevent jet lag?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838266\">",
"      Can supplements or medicines help with jet lag?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838298\">",
"      Does melatonin cause side effects?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838315\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86224\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/48/14091\">",
"      Taking melatonin to prevent jet lag",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/59/21426?source=related_link\">",
"      Patient information: Constipation in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=related_link\">",
"      Patient information: Insomnia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=related_link\">",
"      Patient information: Insomnia treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_9_19603="Patient information: Lung transplant (The Basics)";
var content_f19_9_19603=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87302\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"         Normal lungs",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/11/43186\">",
"         Patient information: Breathing tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/59/5043\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/57/20371\">",
"         Patient information: Cystic fibrosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/31/7666\">",
"         Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39889\">",
"         Patient information: Pulmonary hypertension in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/13/1236\">",
"         Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/50/28450\">",
"         Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lung transplant (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H590589227\">",
"      <span class=\"h1\">",
"       What is a lung transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A lung transplant is a type of surgery in which a doctor replaces 1 or both of your diseased lungs with healthy lungs (",
"      <a class=\"graphic graphic_figure graphicRef67527 \" href=\"UTD.htm?40/17/41237\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      There are different types of lung transplant. Doctors can replace both lungs, which is called a &ldquo;bilateral lung transplant.&rdquo; This type of surgery is done most often. Doctors can also replace only 1 lung, which is called a &ldquo;single lung transplant.&rdquo;",
"     </p>",
"     <p>",
"      Other types of lung transplant are less common. This includes getting a part of a lung from a family member or friend. In rare cases, people get a bilateral lung transplant and a heart transplant at the same time.",
"     </p>",
"     <p>",
"      The type of lung transplant you have depends on your lung disease and individual situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H590589259\">",
"      <span class=\"h1\">",
"       Why might I have a lung transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A lung transplant is done to treat severe lung disease. Different lung conditions can lead to severe lung disease, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chronic obstructive pulmonary disease, called &ldquo;COPD&rdquo; for short",
"       </li>",
"       <li>",
"        Pulmonary fibrosis",
"       </li>",
"       <li>",
"        Cystic fibrosis",
"       </li>",
"       <li>",
"        Alpha-1 antitrypsin deficiency",
"       </li>",
"       <li>",
"        Pulmonary hypertension",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Before you have a lung transplant, your doctor will try all other treatments first. Your doctor will recommend a lung transplant only if all other treatments fail and your lung disease is so severe it could be fatal in the next 1 to 2 years.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H590589274\">",
"      <span class=\"h1\">",
"       What happens before I can get a lung transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before you can get a lung transplant, you need to go through a number of steps.",
"     </p>",
"     <p>",
"      Your doctor will send you to a lung transplant center (a hospital that does lung transplants). At the transplant center, you will have exams and tests. You and your family will also talk with different doctors. They will ask about your:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Other medical conditions and the medicines you take",
"       </li>",
"       <li>",
"        Lifestyle (for example, whether you smoke, drink alcohol, or use illegal drugs)",
"       </li>",
"       <li>",
"        Family and other support system",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Not everyone who is sent to a lung transplant center will get a transplant. To be considered for a lung transplant, you need to meet certain conditions. For example, you need to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have very severe lung disease that hasn&rsquo;t gotten better with other treatments",
"       </li>",
"       <li>",
"        Not have certain infections or medical conditions, such as cancer",
"       </li>",
"       <li>",
"        Agree to not smoke, drink alcohol, or use illegal drugs, which can harm your new lungs",
"       </li>",
"       <li>",
"        Agree to take medicines for the rest of your life after surgery",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you meet all of these conditions, you will be put on a waiting list for new lungs. An organization called &ldquo;UNOS&rdquo; keeps track of everyone on the list. UNOS tries to give lungs to the sickest people first. Your doctors will let UNOS know if your disease gets worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H590589289\">",
"      <span class=\"h1\">",
"       What happens before I can get a lung transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can stay as healthy as possible. To stay as healthy as possible, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get regular exercise &ndash; This will help keep your breathing and other muscles strong. Most people need to do a &ldquo;pulmonary rehab&rdquo; program. In pulmonary rehab, you will learn exercises and ways to breathe.",
"       </li>",
"       <li>",
"        Eat a healthy diet &ndash; This will keep your body strong. To help your surgery and recovery go more smoothly, you should also keep your body at a healthy weight.",
"       </li>",
"       <li>",
"        Get the shots (vaccines) your doctor recommends &ndash; This includes a yearly flu shot. It also includes a shot called the pneumococcal vaccine. These shots can help prevent infections that can further damage your lungs.",
"       </li>",
"       <li>",
"        Stop smoking &ndash; You will need to have stopped smoking for a certain amount of time before you can get on the UNOS list.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H590589304\">",
"      <span class=\"h1\">",
"       What happens when lungs become available?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When lungs become available, UNOS chooses the person who is the best match for them. People who are waiting for a transplant need to carry a cell phone or pager at all times so that they can be reached quickly.",
"     </p>",
"     <p>",
"      When you get called for your lung transplant, you will need to get to the hospital quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H590589319\">",
"      <span class=\"h1\">",
"       What happens after a lung transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After surgery, most people stay in the hospital for a few weeks before going home. In the hospital and at home, your doctors will monitor you and do tests to make sure your new lungs are working correctly. Tests usually include breathing tests, chest X-rays, blood tests, and a procedure called bronchoscopy. During bronchoscopy, a doctor uses a thin tube with a camera and light on the end (called a &ldquo;bronchoscope&rdquo;) to look in your airways.",
"     </p>",
"     <p>",
"      After a lung transplant, people need to take medicines called &ldquo;anti-rejection medicines.&rdquo; These medicines prevent the body&rsquo;s immune (infection-fighting) system from rejecting the new lungs. Normally, the immune system fights infections. It also attacks foreign substances, such as blood that is not your type or new lungs. The anti-rejection medicines will help keep your body from attacking your new lungs.",
"     </p>",
"     <p>",
"      Even though anti-rejection medicines help, they also have side effects of their own. They make it difficult for your body to fight off infections. Because of this, you will also need to take antibiotics to prevent infections.",
"     </p>",
"     <p>",
"      The specific anti-rejection medicines and antibiotics you take can change over time. But you will need to take some anti-rejection medicines for the rest of your life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H590589334\">",
"      <span class=\"h1\">",
"       What problems can people have after a lung transplant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In many cases, people do well after surgery. They can go to work and be active. But a lung transplant is major surgery. Some people have problems after a lung transplant. Some people do not even survive the surgery. The problems that can happen after a lung transplant can happen right after the surgery or a few years later. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rejection of the new lungs &ndash; Even though people take anti-rejection medicines, their body might still reject and attack the new lungs.",
"       </li>",
"       <li>",
"        A narrowing or blockage in an airway",
"       </li>",
"       <li>",
"        A blood clot in the lungs",
"       </li>",
"       <li>",
"        Infections in the lungs",
"       </li>",
"       <li>",
"        Side effects from the anti-rejection medicines &ndash; These medicines have short-term side effects, such as increasing a person&rsquo;s chance of getting infections. They also have long-term side effects, such as increasing a person&rsquo;s chance of getting certain types of cancer.",
"       </li>",
"       <li>",
"        The original lung disease returning",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H590589349\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=see_link\">",
"       Patient information: Cystic fibrosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=see_link\">",
"       Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=see_link\">",
"       Patient information: Pulmonary hypertension in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"       Patient information: Breathing tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"       Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/9/19603?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87302 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19603=[""].join("\n");
var outline_f19_9_19603=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589227\">",
"      What is a lung transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589259\">",
"      Why might I have a lung transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589274\">",
"      What happens before I can get a lung transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589289\">",
"      What happens before I can get a lung transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589304\">",
"      What happens when lungs become available?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589319\">",
"      What happens after a lung transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589334\">",
"      What problems can people have after a lung transplant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590589349\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87302\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/17/41237\">",
"      Normal lungs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=related_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=related_link\">",
"      Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/61/39889?source=related_link\">",
"      Patient information: Pulmonary hypertension in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_9_19604="Left ventricular aneurysm four chamber echocardiogram 1";
var content_f19_9_19604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/62247/4chlvane_conv.mp4?title=Left+ventricular+aneurysm+four+chamber+echocardiogram+1\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram shows a large left ventricular apical aneurysm resulting from an anterior wall myocardial infarction. Also noted is a thinned interventricular septum and anterior left ventricular wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19604=[""].join("\n");
var outline_f19_9_19604=null;
var title_f19_9_19605="Pelvic lateral compression fracture type I";
var content_f19_9_19605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 589px\">",
"   <div class=\"ttl\">",
"    Pelvic lateral compression fracture: Type I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 569px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Type I lateral compression fracture with bilateral superior and inferior rami fractures and left sacral fracture. B) Inlet view showing greater detail of the pelvic ring disruption. C) Outlet view illustrating greater detail of the sacral fracture in addition to the bilateral rami fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19605=[""].join("\n");
var outline_f19_9_19605=null;
var title_f19_9_19606="Fat emulsion: Pediatric drug information";
var content_f19_9_19606=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fat emulsion: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/29/17878?source=see_link\">",
"    see \"Fat emulsion: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/34/5668?source=see_link\">",
"    see \"Fat emulsion: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intralipid&reg;;",
"     </li>",
"     <li>",
"      Liposyn&reg; III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Intralipid&reg;;",
"     </li>",
"     <li>",
"      Liposyn&reg; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Caloric Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Intravenous Nutritional Therapy",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12674621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parenteral nutrition:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Fat emulsion should not exceed 60% of the total daily calories. At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: I.V.: Initial dose: 1-2 g/kg/day, increase by 0.5-1 g/kg/day to a maximum of 3-3.5 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010); do not exceed 1 g/kg in 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Term neonates: I.V.: Initial dose: 1-2 g/kg/day, increase by 0.5-1 g/kg/day to a maximum of 3 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Localized anesthetic toxicity:",
"     </b>",
"     Full-term neonate: Very limited data available: 20% fat emulsion: I.V.: 1",
"     <b>",
"      mL",
"     </b>",
"     /kg was reported  in a single case report in a 2-day-old neonate undergoing caudal epidural block for a urologic procedure (Lin, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/29/17878?source=see_link\">",
"      see \"Fat emulsion: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parenteral nutrition:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Fat emulsion should not exceed 60% of the total daily calories. At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants: I.V.: Initial dose: 1-2 g/kg/day, increase by 0.5-1 g/kg/day to a maximum of 3 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-10 years: I.V.: Initial dose: 1-2 g/kg/day, increase by 0.5-1 g/kg/day to a maximum of 2-3 g/kg/day depending upon the needs/nutritional goals; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;11 years, Adolescents, and Adults: I.V.: Initial dose: 1 g/kg/day; not to exceed 500 mL 20% fat emulsion on the first day of therapy, increase by 1 g/kg/day to a maximum of 2.5 g/kg/day; daily dose infused over 24 hours; total infusion time may be incrementally increased (ie, cycled) to a maximum daily infusion over 12 hours (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Essential fatty acid deficiency (EFAD), prevention:",
"     </b>",
"     Children, Adolescents, and Adults: I.V.: Administer 8% to 10% of total caloric intake as fat emulsion; infuse 2-3 times weekly; may need to increase dose during stress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Local anesthetic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: Limited data available: 20% fat emulsion: I.V.: 0.8-3",
"     <b>",
"      mL",
"     </b>",
"     /kg bolus has been used successfully in several pediatric case reports (1 month-13 years) (Fuzaylov, 2010; Ludot, 2008; Shah, 2009; Wong, 2010); a single case report in a 6-year-old described use of a continuous I.V. infusion at 0.25",
"     <b>",
"      mL",
"     </b>",
"     /kg/minute to a total dose of 8",
"     <b>",
"      mL",
"     </b>",
"     /kg following the bolus dose (Wong, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 20% fat emulsion: I.V.: Infuse 1.5 mL/kg over 1 minute, followed immediately by an infusion of 0.25 mL/kg/minute; continue chest compressions (lipid must circulate). Repeat the bolus 1-2 times as needed for persistent asystole, pulseless electrical activity, or re-emergence of hemodynamic instability. Continue I.V. infusion for at least 10 minutes after hemodynamic stability is restored; discontinue within 1 hour, if possible. Increase the infusion rate to 0.5 mL/kg/minute if hemodynamic instability persists or recurs (ACMT, 2010; Neal, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, emulsion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intralipid&reg;: 20% (100 mL, 250 mL, 500 mL, 1000 mL); 30% (500 mL) [contains aluminum, egg yolk phospholipid, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liposyn&reg; III: 10% (250 mL, 500 mL); 20% (250 mL, 500 mL); 30% (500 mL) [contains aluminum, egg yolk phospholipid, soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parenteral nutrition:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10% and 20% emulsions: May be simultaneously infused with amino acid and dextrose mixtures by means of Y-connector located near infusion site into either central or peripheral line or administered in total nutrient mixtures (3-in-1) with amino acids, dextrose, and other nutrients. At the bedside, fat emulsion solution should be elevated higher than other parenteral fluids to prevent it running up into other I.V. lines due to its low specific gravity. For Intralipid&reg;: Do not use &lt;1.2 micron filter; for Liposyn&reg; III: Do not use a filter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     30% emulsion:",
"     <b>",
"      Intended only for use as component of 3-in-1 or total nutrient admixture",
"     </b>",
"     ; not intended for direct infusion; must be further diluted to a final concentration not to exceed 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates, Infants, and Children:",
"     <b>",
"      Note:",
"     </b>",
"     Premature and/or septic infants may require reduced infusion rates; do not exceed 1 g/kg in 4 hours in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10% emulsions: Avoid use of 10% fat emulsion in preterm infants as a greater accumulation of plasma lipids occurs with the greater phospholipid load of the 10% fat emulsion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intralipid&reg;: Initiate at &le;0.1",
"     <b>",
"      mL",
"     </b>",
"     /minute for 10-15 minutes; if no untoward effects occur, the infusion rate may be increased to 1",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Liposyn&reg; III: Initiate at 0.1",
"     <b>",
"      mL",
"     </b>",
"     /minute for 15 minutes, may increase to &le;100",
"     <b>",
"      mL/hour",
"     </b>",
"     if tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     20% emulsions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intralipid&reg;:  Initiate at &le;0.05",
"     <b>",
"      mL",
"     </b>",
"     /minute for 10-15 minutes; if no untoward effects occur, the infusion rate may be increased to 0.5",
"     <b>",
"      mL",
"     </b>",
"     /kg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Liposyn&reg; III: Initiate at 0.1",
"     <b>",
"      mL",
"     </b>",
"     /minute for 15 minutes, may increase to &le;50",
"     <b>",
"      mL/hour",
"     </b>",
"     if tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     10% emulsions (Intralipid&reg;; Liposyn&reg; III): Initiate at 1",
"     <b>",
"      mL",
"     </b>",
"     /minute for 15-30 minutes; if no untoward effects occur, the infusion rate may be increased to 2",
"     <b>",
"      mL",
"     </b>",
"     /minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     20% emulsions (Intralipid&reg;; Liposyn&reg; III): Initiate at 0.5 mL/minute for 15-30 minutes; if no untoward effects occur, the infusion rate may be increased to 1",
"     <b>",
"      mL",
"     </b>",
"     /minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Local anesthetic toxicity:",
"     </b>",
"     20% emulsion: Administer initial bolus undiluted over 1 minute; may be administered either peripherally or centrally; bolus may be followed by a continuous infusion depending on clinical scenario. Chest compressions should continue during administration if patient is in cardiac arrest. Continue the infusion for at least 10 minutes after hemodynamic stability is restored. The infusion rate may be increased if hemodynamic instability recurs (ACMT, 2010; Neal, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intralipid&reg;: Store below 25&deg;C (77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liposyn&reg; III: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not freeze; do not store in partly used containers; fat emulsion can support the growth of various organisms. Do not use if emulsion appears to be layering out; exposure to light, particularly phototherapy light, used in treatment or prevention of hyperbilirubinemia has been associated with increased lipid oxidation; the clinical significance remains to be established; do not mix other drugs with fat emulsion; only heparin at a concentration of 1-2 units/mL may be added to fat emulsion",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Source of calories and essential fatty acids for patients requiring parenteral nutrition of extended duration (FDA approved in all ages); prevention and treatment of essential fatty acid deficiency (EFAD) (FDA approved in all ages); has also been used for treatment of local anesthetic-induced cardiac arrest unresponsive to conventional resuscitation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14599185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Intralipid&reg; may be confused with ViperSlide&trade; (lubricant used during atherectomy procedures)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare but important or life-threatening: Allergic reactions, brown pigment deposition in the reticuloendothelial system (&ldquo;intravenous fat pigment&rdquo;), cholestasis, cyanosis, hepatomegaly, hypercoagulability, hyperlipidemia, infusion site irritation, jaundice, leukopenia, liver function tests increased, pancreatitis, overloading syndrome (focal seizures, fever, leukocytosis, hepatomegaly, splenomegaly, shock), thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fat emulsion or any component; disturbances of normal fat metabolism (eg, pathologic hyperlipidemia, lipoid nephrosis, pancreatitis with hyperlipemia)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe liver damage, pulmonary disease, anemia, or blood coagulation disorders or when there is risk for fat embolism; use with caution in cholestatic patients or in those at risk for parenteral nutrition-associated cholestasis. When cholestatsis occurs, fat emulsion may be temporarily decreased or stopped. Use with caution in patients with severe egg or soybean allergies.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fat emulsions contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deaths in preterm neonates after infusion of I.V. fat emulsions have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Autopsy findings included intravascular fat accumulation in the lungs. I.V. fat emulsion should be used carefully in preterm neonates adhering to maximum daily dosages and infusing as slowly as possible. Preterm infants have a decreased ability to eliminate infused fat and must be monitored closely using triglyceride or plasma free fatty acid concentrations. Avoid use of 10% fat emulsion in preterm infants as a greater accumulation of plasma lipids occurs with the greater phospholipid load of the 10% fat emulsion. Frequent platelet counts (some advise daily) should also be obtained in neonatal patients receiving fat emulsion. Monitor liver function tests when using as long-term therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fat emulsion in a 3-in-1 mixture may obscure the presence of a precipitate; follow compounding guidelines, especially regarding calcium and phosphate compatibility. Thirty percent fat emulsions are not intended for direct I.V. infusion and dilution with another I.V. fluid (eg, NS or SWI) does not produce a dilution equivalent to 10% or 20% I.V. fat emulsion; such dilutions should not be administered by direct I.V. infusion.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5062137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been conducted. Indications for fat emulsion therapy in pregnant women are the same as in nonpregnant women. The ASPEN guidelines for parenteral and enteral nutrition state that intravenous fat emulsion may be used safely in pregnant women to provide calories and prevent essential fatty acid deficiency (ASPEN Guidelines, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum triglycerides, free fatty acids, platelets (neonates), liver enzymes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatty acids are essential for normal structure and function of cell membranes; infusion of fatty acids as I.V. fat emulsion provides a source of calories and essential fatty acids normally obtained in the enteral diet",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In local anesthetic toxicity, exogenous lipids provide an alternative source of binding of lipid-soluble local anesthetics (Rowlingson, 2008), commonly known as the \"lipid sink\" effect. This is more relevant to bupivacaine, levobupivacaine, and ropivacaine than mepivacaine and prilocaine. High lipid partition constant and large volumes of distribution are good predictors of success when using lipid therapy (French, 2011). Lipid administration may also affect the heart in a metabolically advantageous way by improving fatty acid transport (Weinberg, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fat emulsion has been used successfully as a treatment in a pediatric patient experiencing local anesthetic cardiovascular toxicity (Ludot, 2008) and also in animal studies and several human case reports in which cardiovascular toxicity was unresponsive to conventional resuscitation and antidotal measures. May consider use of 20% fat emulsion when local anesthetic toxicity is likely and conventional methods are unsuccessful. Continue CPR throughout treatment with lipid emulsion. Additional information is available at file://www.lipidrescue.org.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caloric content: 10% emulsion = 1.1 Kcal/mL; 20% emulsion = 2 Kcal/mL; 30% emulsion = 3 Kcal/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphorus: ~1.5 mMol/100 mL of emulsion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     10% and 20% emulsions are isotonic and may be administered peripherally",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Medical Toxicology (ACMT), \"Interim Guidance for the Use of Lipid Resuscitation Therapy,\" 2010. Available at file://www.acmt.net/cgi/page.cgi?aid=3384&amp;_id=52&amp;zine=show",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ASPEN Board of Directors and the Clinical Guidelines Task Force, \"Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2002, 26(1 Suppl):1SA-138SA.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/11841046/pubmed\" id=\"11841046\" target=\"_blank\">",
"        11841046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carney LN, Nepa A, Cohen SS, et al, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds,",
"      <i>",
"       The A.S.P.E.N Pediatric Nutrition Support Core Curriculum",
"      </i>",
"      , Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 440-1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colomb V, Jobert-Giraud A, Lacaille F, et al, \"Role of Lipid Emulsions in Cholestasis Associated With Long-Term Parenteral Nutrition in Children,\"",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2000, 24(6):345-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/11071594/pubmed\" id=\"11071594\" target=\"_blank\">",
"        11071594",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corcoran W, Butterworth J, Weller RS, et al, \"Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2006, 103(5):1322-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/17056977/pubmed\" id=\"17056977\" target=\"_blank\">",
"        17056977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Health &amp; Human Services, Food and Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foxall G, McCahon R, Lamb J, et al, \"Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2007, 62(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/17448066/pubmed\" id=\"17448066\" target=\"_blank\">",
"        17448066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French D, Smollin C, Ruan W, et al, &ldquo;Partition Constant and Volume of Distribution as Predictors of Clinical Efficacy of Lipid Rescue for Toxicological Emergencies,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2011, 49(9):801-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/21981684/pubmed\" id=\"21981684\" target=\"_blank\">",
"        21981684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuzaylov G, Ying B, Tang Y, et al, \"Successful Resuscitation After Inadvertent Intravenous Injection of Bupivacaine in an Adolescent,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2010, 20(10):958-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/20849502/pubmed\" id=\"20849502\" target=\"_blank\">",
"        20849502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haumont D, Richelle M, Deckelbaum RJ, et al, &ldquo;Effect of Liposomal Content of Lipid Emulsions of Plasma Lipid Concentrations in Low Birth Weight Infants Receiving Parenteral Nutrition,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(5 Pt 1):759-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/1432430/pubmed\" id=\"1432430\" target=\"_blank\">",
"        1432430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin EP and Aronson LA, \"Successful Resuscitation of Bupivacaine-Induced Cardiotoxicity in a Neonate,\"",
"      <i>",
"       Paediatr Anaesth",
"      </i>",
"      , 2010, 20(10):955-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/20849501/pubmed\" id=\"20849501\" target=\"_blank\">",
"        20849501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litz RJ, Popp M, Stehr SN, et al, \"Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2006, 61(8):800-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/16867094/pubmed\" id=\"16867094\" target=\"_blank\">",
"        16867094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ludot H, Tharin JY, Belouadah M, et al, \"Successful Resuscitation After Ropivacaine and Lidocaine-Induced Ventricular Arrhythmia Following Posterior Lumbar Plexus Block in a Child,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2008, 106(5):1572-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/18420879/pubmed\" id=\"18420879\" target=\"_blank\">",
"        18420879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition. Task Force for the Revision of Safe Practices for Parenteral Nutrition,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, \"American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,\"",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neuzil J, Darlow BA, Inder TE, et al, &ldquo;Oxidation of Parenteral Lipid Emulsion by Ambient and Phototherapy Lights: Potential Toxicity of Routine Parenteral Feeding,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(5 Pt 1):785-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/7752007/pubmed\" id=\"7752007\" target=\"_blank\">",
"        7752007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowlingson JC, \"Lipid Rescue: A Step Forward in Patient Safety? Likely So!\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2008, 106(5):1333-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/18420839/pubmed\" id=\"18420839\" target=\"_blank\">",
"        18420839",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shah S, Gopalakrishnan S, Apuya J, et al, \"Use of Intralipid in an Infant With Impending Cardiovascular Collapse Due to Local Anesthetic Toxicity,\"",
"      <i>",
"       J Anesth",
"      </i>",
"      , 2009, 23(3):439-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/19685131/pubmed\" id=\"19685131\" target=\"_blank\">",
"        19685131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shin JI, Namgung R, Park MS, et al, \"Could Lipid Infusion Be a Risk for Parenteral Nutrition-Associated Cholestasis in Low Birth Weight Neonates?\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2008, 167(2):197-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/17436017/pubmed\" id=\"17436017\" target=\"_blank\">",
"        17436017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinberg GL, Ripper R, Murphy P, et al, &ldquo;Lipid Infusion Accelerates Removal of Bupivacaine and Recovery From Bupivacaine Toxicity in the Isolated Rat Heart,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2006, 31(4):296-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/16857549/pubmed\" id=\"16857549\" target=\"_blank\">",
"        16857549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong GK, Joo DT, and McDonnell C, \"Lipid Resuscitation in a Carnitine Deficient Child Following Intravascular Migration of an Epidural Catheter,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2010, 65(2):192-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/9/19606/abstract-text/19849674/pubmed\" id=\"19849674\" target=\"_blank\">",
"        19849674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13296 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19606=[""].join("\n");
var outline_f19_9_19606=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708777\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170060\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170061\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058686\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12674621\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058681\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170033\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058690\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058683\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058689\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14599185\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170078\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058692\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058680\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058679\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5062137\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058685\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058678\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058693\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13296|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/29/17878?source=related_link\">",
"      Fat emulsion: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/34/5668?source=related_link\">",
"      Fat emulsion: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_9_19607="Elbow anatomy and radiographic diagnosis of elbow fracture in children";
var content_f19_9_19607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Elbow anatomy and radiographic diagnosis of elbow fracture in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19607/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19607/contributors\">",
"     Leticia Manning Ryan, MD, MPH, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19607/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19607/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19607/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/9/19607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of anatomy, normal bony development, and radiographic features of the pediatric elbow are essential to prompt recognition and treatment of elbow injuries in children. In most instances, plain radiographs are adequate to detect fractures that pose a threat to future growth and function. On occasion, additional modalities (eg, ultrasound, magnetic resonance imaging, or arthrography) are needed to identify and fully delineate elbow fractures, especially in infants and young children.",
"   </p>",
"   <p>",
"    This review discusses the anatomy, plain radiographic views, and radiographic interpretation of the pediatric elbow. Findings pertinent to specific elbow fractures in children are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link\">",
"     \"Evaluation and management of supracondylar fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19175?source=see_link\">",
"     \"Evaluation and management of condylar elbow fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=see_link\">",
"     \"Epicondylar and transphyseal elbow fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Elbow joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;The elbow is a complex hinge joint composed of three separate articulations (",
"    <a class=\"graphic graphic_figure graphicRef66874 \" href=\"UTD.htm?36/29/37330\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulnohumeral - Between the trochlea of the humerus and the olecranon of the ulna",
"     </li>",
"     <li>",
"      Radiohumeral - Between the capitellum of the humerus and the radial head",
"     </li>",
"     <li>",
"      Radioulnar - Between the proximal radius and ulna",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the medial and lateral epicondyles are both extraarticular, the full articular surface of the distal humerus is intraarticular [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An anterior fat pad and a posterior fat pad are located between the capsule and the distal end of the humerus (",
"    <a class=\"graphic graphic_figure graphicRef68355 \" href=\"UTD.htm?40/58/41903\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/2\">",
"     2",
"    </a>",
"    ]. The appearance of these fat pads assists in the radiographic diagnosis of elbow fractures. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Fat pads'",
"    </a>",
"    below.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ossification centers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are six growth centers within the elbow joint that appear in a consecutive manner within predictable age ranges [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/3\">",
"     3",
"    </a>",
"    ]. Their appearance is usually earlier in girls than boys (",
"    <a class=\"graphic graphic_table graphicRef61591 \" href=\"UTD.htm?12/19/12604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/4\">",
"     4",
"    </a>",
"    ]. These secondary ossification centers later fuse to create the mature bony elbow. Similar to the appearance of the ossification centers, fusion proceeds at predictable age ranges and usually occurs earlier in girls than in boys (",
"    <a class=\"graphic graphic_figure graphicRef73818 graphicRef79600 \" href=\"UTD.htm?28/1/28695\">",
"     figure 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Normal ossification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Growth plate (physis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growing long bones in children are composed of the following segments: diaphysis (shaft), metaphysis (where the bone flares), physis (growth plate), and epiphysis (secondary ossification center) (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 4",
"    </a>",
"    ). The physis is composed of cartilage and is a transition zone located between the epiphysis and diaphysis of an immature long bone. This is a highly metabolically active and rapidly changing area of bone where longitudinal growth of long bones occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The growth and change that occur at a growth plate promote rapid healing of fractures. However, injury to the physis itself can lead to asymmetric growth and subsequent deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ]. The epiphyseal cartilage cells stop duplicating at the end of puberty. The entire cartilage is eventually replaced by bone, and epiphyseal lines remain at the site [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast to the proximal humeral physis, the distal humeral physis contributes little (15 to 20 percent) to the overall longitudinal growth of the humerus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vascular anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brachial artery is superficial to the brachialis muscle along the anteromedial aspect of the humerus. As the brachial artery passes anterior to the distal humerus, an extensive collateral circulation develops. As the artery extends into the forearm, it splits into the radial and ulnar arteries (",
"    <a class=\"graphic graphic_figure graphicRef82540 \" href=\"UTD.htm?22/52/23365\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The brachial artery is especially prone to injury following a supracondylar fracture. \"Scraping\" of the brachial artery by the bony fragment may result in intimal damage to the vessel; this injury may subsequently lead to thrombosis and vascular insufficiency. Because of the extensive collateral circulation present at the elbow, it is rare for the ischemia of the arm to occur from complete occlusion of the brachial artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and management of supracondylar fractures in children\", section on 'Vascular anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nerve anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median nerve crosses the elbow with the brachial artery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/11\">",
"     11",
"    </a>",
"    ]. The radial nerve runs between the brachialis and brachioradialis muscles before crossing the elbow and penetrating the supinator muscle. The ulnar nerve crosses the elbow posterior to the medial epicondyle (",
"    <a class=\"graphic graphic_figure graphicRef82540 \" href=\"UTD.htm?22/52/23365\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The median and radial nerves are susceptible to injury following supracondylar fractures after elbow hyperextension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/11\">",
"     11",
"    </a>",
"    ]. The ulnar nerve is susceptible to injury when a direct blow to the posterior aspect of the elbow or supracondylar fracture with elbow hyperflexion occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link&amp;anchor=H35#H35\">",
"     \"Evaluation and management of supracondylar fractures in children\", section on 'Neurologic deficit'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PLAIN RADIOGRAPHIC VIEWS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs should be obtained in children who present with localized tenderness, deformity, or swelling of the elbow and known or suspected trauma. Plain radiographs should be obtained in at least two views: an anterior-posterior view in extension and a lateral view at 90 degrees of flexion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior-posterior view shows the epicondyles (medial and lateral) and the articular surfaces (radiocapitellar and ulnotrochlear).",
"     </li>",
"     <li>",
"      The lateral view shows the relationship between the bones of the distal humerus and the proximal forearm and the relationship of the anterior and posterior fat pads to the humerus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third view, the lateral oblique view, shows the radiocapitellar joint, medial epicondyle, radioulnar joint, and the coronoid process. This view can be helpful in diagnosing subtle lateral condyle fractures and assessing displacement but is not always obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PLAIN RADIOGRAPH INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of the pediatric elbow radiograph is challenging due to the different stages of ossification and predominance of cartilage present prior to ossification [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several radiographic signs and lines have been described to assist with the radiographic diagnosis of elbow fractures. These radiographic signs are reliable only if the elbow has been properly positioned for the radiographs; the importance of a true lateral view in particular cannot be overemphasized (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56647 \" href=\"UTD.htm?23/2/23586\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71799 \" href=\"UTD.htm?20/33/21009\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Normal ossification",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are six ossification centers in the pediatric elbow (",
"    <a class=\"graphic graphic_table graphicRef61591 \" href=\"UTD.htm?12/19/12604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/1\">",
"     1",
"    </a>",
"    ]. The following acronym is a useful memory aid for recalling their radiographic order of appearance (",
"    <a class=\"graphic graphic_figure graphicRef73226 \" href=\"UTD.htm?16/58/17313\">",
"     figure 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C - Capitellum",
"     </li>",
"     <li>",
"      R - Radial head",
"     </li>",
"     <li>",
"      I - Internal (medial) epicondyle",
"     </li>",
"     <li>",
"      T - Trochlea",
"     </li>",
"     <li>",
"      O - Olecranon",
"     </li>",
"     <li>",
"      E - External (lateral) epicondyle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first ossification center, the capitellum, appears at about one year of age and each subsequent ossification site in the mnemonic appears approximately in a two year progression (ie, 1, 3, 5, 7, 9, and 11 years). However, this timing is highly variable and markedly differs by gender. The exact mean age, range of appearance, and degree of difference by gender is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef61591 \" href=\"UTD.htm?12/19/12604\">",
"     table 1",
"    </a>",
"    ). These secondary ossification centers later fuse to create the mature bony elbow. If it is difficult to distinguish the normal growth center from a fracture fragment, comparison views of the uninjured elbow may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Anterior humeral line",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal elbow, a line drawn through the anterior cortex of the humerus intersects the capitellum in its middle third (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"     image 1",
"    </a>",
"    ). Because the most common mechanism of injury to the elbow is hyperextension, posterior displacement of the distal humerus is common when a fracture occurs. In these cases, the anterior humeral line passes through the anterior third of the capitellum or fails to intersect it (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63886 \" href=\"UTD.htm?25/7/25712\">",
"     image 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of abnormalities of the anterior humeral line in children less than two years of age is complicated by the variable rates of ossification of the capitellum; comparison views can be helpful in uncertain cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radial head alignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radial head should point toward the capitellum on all views [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/3\">",
"     3",
"    </a>",
"    ]. The clinician should suspect a lateral condyle fracture or Monteggia fracture when radial head dislocation is evident (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72414 \" href=\"UTD.htm?42/32/43534\">",
"     image 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fat pads",
"    </span>",
"    &nbsp;&mdash;&nbsp;Displacement of fat pads on radiographs is an indirect indicator of hemorrhage or an elbow joint effusion (",
"    <a class=\"graphic graphic_figure graphicRef70692 \" href=\"UTD.htm?20/7/20595\">",
"     figure 8",
"    </a>",
"    ). In the setting of known or suspected trauma, the presence of an abnormal fat pad sign should be considered a marker of an occult fracture and an indication for careful immobilization and close follow-up (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55523 \" href=\"UTD.htm?23/16/23823\">",
"     image 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Anterior fat pad",
"    </span>",
"    &nbsp;&mdash;&nbsp;An anterior fat pad can be a normal variant when it appears as a narrow radiolucent strip superior to the radial head and anterior to the distal humerus. A wide anterior fat pad, however, is known as a \"sail\"' sign and may be indicative of an occult fracture (",
"    <a class=\"graphic graphic_figure graphicRef70692 \" href=\"UTD.htm?20/7/20595\">",
"     figure 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/6\">",
"     6",
"    </a>",
"    ]. In one study of 197 children (25 percent with fractures) undergoing elbow radiographs in a pediatric emergency department, an abnormal anterior fat pad, as interpreted by a pediatric radiologist, had a sensitivity of 96 percent and a positive predictive value of 64 percent for an occult elbow fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, the presence of a posterior fat pad in these patients had a sensitivity of 88 percent and a positive predictive value of 79 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Posterior fat pad",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior fat pad is not visible in normal children but usually appears as a radiolucency posterior to the distal humerus and adjacent to the olecranon fossa in children with a distal humeral fracture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55523 \" href=\"UTD.htm?23/16/23823\">",
"     image 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/6\">",
"     6",
"    </a>",
"    ].The presence of a posterior fat pad on radiograph indicates an effusion of the elbow joint caused by significant trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/15\">",
"     15",
"    </a>",
"    ]. The sensitivity of a posterior fat pad for an occult fracture varies significantly in the literature with the largest study suggesting a sensitivity of approximately 88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Carrying angle",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the arms in anatomic position (eg, extended with palms facing forward), the normal carrying angle of the elbow is approximately 5 to 15 degrees, thus placing the hands and forearms slightly away from the body.",
"   </p>",
"   <p>",
"    Varus deformity of the elbow, also called cubitus varus, results in the forearm pointing towards the body when the arm is anatomic position with the elbow sticking out (\"gunstock deformity\") (",
"    <a class=\"graphic graphic_figure graphicRef63539 \" href=\"UTD.htm?17/52/18255\">",
"     figure 9",
"    </a>",
"    ). This abnormality may be seen after inadequate alignment of a displaced supracondylar fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link&amp;anchor=H36#H36\">",
"     \"Evaluation and management of supracondylar fractures in children\", section on 'Cubitus varus deformity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Valgus deformity of the elbow, also called cubitus valgus, results in an exaggerated carrying angle. This abnormality may occur after inadequate union or alignment of lateral condyle fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50518 \" href=\"UTD.htm?30/32/31233\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several angles are used to estimate the carrying angle radiographically [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baumann angle - Although some variation in definition exists within the literature, the angle originally described by Baumann is defined as the angle between the physeal line of the lateral condyle of the humerus and the long axis of the humeral shaft (",
"      <a class=\"graphic graphic_figure graphicRef60474 \" href=\"UTD.htm?18/14/18671\">",
"       figure 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. The normal angle is between 75 and 80 degrees; a larger angle suggests that a varus deformity exists. This angle may be helpful in determining the adequacy of reduction for displaced distal humeral fractures.",
"     </li>",
"     <li>",
"      Humeral-ulnar angle - This angle is formed by a longitudinal line along the humeral shaft that is bisected by a line that is longitudinal to the ulna and is regarded as the most accurate in determining the true carrying angle of the elbow (normal value: 5 to 15 degrees) (",
"      <a class=\"graphic graphic_figure graphicRef80190 \" href=\"UTD.htm?35/61/36830\">",
"       figure 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medial epicondylar epiphyseal angle - This angle describes a line down the axis of humerus that intersects with a line along the medial epicondylar physis and is 34 to 42 degrees in normal children [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FURTHER IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional imaging (eg, ultrasound, magnetic resonance imaging, arthrography) is rarely needed to manage children with elbow fractures, but may be helpful in selected circumstances (eg, young children and infants, distal humeral transphyseal fractures, intraarticular soft tissue foreign bodies, condylar fractures). Consultation with a radiologist or orthopedic surgeon will generally be obtained before deciding upon the need for further studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    selecting the most appropriate modality. In situations where appropriately expert consultants are not available to assist in the diagnosis of these subtle injuries, the emergency physician may place the patient in a posterior splint and arrange for follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and young children with elbow injuries may have significant injury of the unossified epiphyses in the elbow region. Ultrasound may be helpful to identify fractures, physeal injuries, and dislocations that are not apparent on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although plain radiography is adequate to identify significant elbow fractures in most patients, MRI may delineate additional features that may impact management, especially in children with lateral condyle fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Arthrography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In difficult cases, arthrography has been a useful adjunct to help delineate condylar fractures with intraarticular extension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/35/20018?source=see_link\">",
"       \"Patient information: Elbow fracture in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The elbow is a complex hinge joint composed of three separate articulations (",
"      <a class=\"graphic graphic_figure graphicRef66874 \" href=\"UTD.htm?36/29/37330\">",
"       figure 1",
"      </a>",
"      ) and (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Elbow joint'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ulnohumeral - Between the trochlea of the humerus and the olecranon of the ulna",
"     </li>",
"     <li>",
"      Radiohumeral - Between the capitellum of the humerus and the radial head",
"     </li>",
"     <li>",
"      Radioulnar - Between the proximal radius and ulna",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children, there are six ossification centers that vary in appearance depending on the age and gender of the child (",
"      <a class=\"graphic graphic_table graphicRef61591 \" href=\"UTD.htm?12/19/12604\">",
"       table 1",
"      </a>",
"      ). These secondary ossification centers later fuse to create the mature bony elbow (",
"      <a class=\"graphic graphic_figure graphicRef73818 graphicRef79600 \" href=\"UTD.htm?28/1/28695\">",
"       figure 3A-B",
"      </a>",
"      ). The following acronym is a useful memory aid for recalling their radiographic order of appearance (",
"      <a class=\"graphic graphic_figure graphicRef73226 \" href=\"UTD.htm?16/58/17313\">",
"       figure 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ossification centers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Normal ossification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      C - Capitellum",
"     </li>",
"     <li>",
"      R - Radial head",
"     </li>",
"     <li>",
"      I - Internal (medial) epicondyle",
"     </li>",
"     <li>",
"      T - Trochlea",
"     </li>",
"     <li>",
"      O - Olecranon",
"     </li>",
"     <li>",
"      E - External (lateral) epicondyle",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Interpreting elbow radiographs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiographs should be obtained in children who present with localized tenderness or swelling of the elbow and known or suspected trauma. Plain radiographs should be obtained in at least two views: an anterior-posterior view in extension and a lateral view at 90 degrees of flexion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71799 \" href=\"UTD.htm?20/33/21009\">",
"       figure 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Plain radiographic views'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comparison views of the unaffected elbow may be helpful to distinguish a fracture from a normal ossification center in infants and young children with condylar or epicondylar elbow fractures. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Normal ossification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the normal elbow, a line drawn through the anterior cortex of the humerus intersects the capitellum in its middle third (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"       image 1",
"      </a>",
"      ). Because the most common mechanism of injury to the elbow is hyperextension, posterior displacement of the distal humerus is common when a fracture occurs, and the anterior humeral line will pass through the anterior third of the capitellum or fail to intersect it (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63886 \" href=\"UTD.htm?25/7/25712\">",
"       image 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Anterior humeral line'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radial head should point toward the capitellum on all views [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19607/abstract/3\">",
"       3",
"      </a>",
"      ]. The clinician should suspect an elbow dislocation, lateral condyle fracture, or Monteggia fracture when radial head dislocation is evident (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79906 \" href=\"UTD.htm?29/4/29760\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72414 \" href=\"UTD.htm?42/32/43534\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radial head alignment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An anterior fat pad and a posterior fat pad are located between the capsule and the distal end of the humerus (",
"      <a class=\"graphic graphic_figure graphicRef68355 \" href=\"UTD.htm?40/58/41903\">",
"       figure 2",
"      </a>",
"      ). Visualization of the posterior fat pad or displacement of the anterior fat pad on radiographs is an indirect indicator of hemorrhage or an elbow joint effusion often arising from an occult fracture (",
"      <a class=\"graphic graphic_figure graphicRef70692 \" href=\"UTD.htm?20/7/20595\">",
"       figure 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55523 \" href=\"UTD.htm?23/16/23823\">",
"       image 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fat pads'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional imaging (eg, ultrasound, magnetic resonance imaging, arthrography) is rarely needed to manage children with elbow fractures, but may be helpful in selected circumstances (eg, young children and infants, intraarticular soft tissue foreign bodies, condylar fractures, distal humeral transphyseal fractures). Consultation with a radiologist or orthopedic surgeon with appropriate pediatric expertise will generally be obtained before deciding upon the need for further studies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      selecting the most appropriate modality. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Further imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bachman D, Santora S. Orthopedic trauma. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, et al.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1538.",
"    </li>",
"    <li>",
"     Green NE. Fractures and dislocations about the elbow. In: Skeletal Trauma in Children, 3rd, Green NE, Swiontkowski MF.  (Eds), WB Saunders, Philadelphia 2003. p.257.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/3\">",
"      Shrader MW. Pediatric supracondylar fractures and pediatric physeal elbow fractures. Orthop Clin North Am 2008; 39:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/4\">",
"      Elgenmark, O. The normal development of the ossification centers during infancy and childhood. Acta Paediatr 1946; Suppl 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/5\">",
"      Della-Giustina K, Della-Giustina DA. Emergency department evaluation and treatment of pediatric orthopedic injuries. Emerg Med Clin North Am 1999; 17:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/6\">",
"      Carson S, Woolridge DP, Colletti J, Kilgore K. Pediatric upper extremity injuries. Pediatr Clin North Am 2006; 53:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/7\">",
"      Benjamin, HJ, Hang, BT. Common acute upper extremity injuries in sports. Clin Pediatr Emerg Med 2007; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/8\">",
"      Iannotti JP. Growth plate physiology and pathology. Orthop Clin North Am 1990; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/9\">",
"      Murray DW, Wilson-MacDonald J, Morscher E, et al. Bone growth and remodelling after fracture. J Bone Joint Surg Br 1996; 78:42.",
"     </a>",
"    </li>",
"    <li>",
"     Price C, Phillips J, Devito D. Management of fractures. In: Lovell &amp; Winter's Pediatric Orthopaedics, Morrissy, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.1319.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/11\">",
"      Campbell CC, Waters PM, Emans JB, et al. Neurovascular injury and displacement in type III supracondylar humerus fractures. J Pediatr Orthop 1995; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/12\">",
"      Baratz M, Micucci C, Sangimino M. Pediatric supracondylar humerus fractures. Hand Clin 2006; 22:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/13\">",
"      Villarin LA Jr, Belk KE, Freid R. Emergency department evaluation and treatment of elbow and forearm injuries. Emerg Med Clin North Am 1999; 17:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/14\">",
"      Blumberg SM, Kunkov S, Crain EF, Goldman HS. The predictive value of a normal radiographic anterior fat pad sign following elbow trauma in children. Pediatr Emerg Care 2011; 27:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/15\">",
"      Donnelly LF, Klostermeier TT, Klosterman LA. Traumatic elbow effusions in pediatric patients: are occult fractures the rule? AJR Am J Roentgenol 1998; 171:243.",
"     </a>",
"    </li>",
"    <li>",
"     Beaty JH, Kasser JR. The elbow region: General concepts in the pediatric patient. In: Rockwood and Wilkin's Fractures in Children, 5th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.563.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/17\">",
"      Acton JD, McNally MA. Baumann's confusing legacy. Injury 2001; 32:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/18\">",
"      Biyani A, Gupta SP, Sharma JC. Determination of medial epicondylar epiphyseal angle for supracondylar humeral fractures in children. J Pediatr Orthop 1993; 13:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/19\">",
"      Davidson RS, Markowitz RI, Dormans J, Drummond DS. Ultrasonographic evaluation of the elbow in infants and young children after suspected trauma. J Bone Joint Surg Am 1994; 76:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/20\">",
"      Zuazo I, Bonnefoy O, Tauzin C, et al. Acute elbow trauma in children: role of ultrasonography. Pediatr Radiol 2008; 38:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/21\">",
"      Horn BD, Herman MJ, Crisci K, et al. Fractures of the lateral humeral condyle: role of the cartilage hinge in fracture stability. J Pediatr Orthop 2002; 22:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/22\">",
"      Vocke-Hell AK, Schmid A. Sonographic differentiation of stable and unstable lateral condyle fractures of the humerus in children. J Pediatr Orthop B 2001; 10:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/23\">",
"      Pudas T, Hurme T, Mattila K, Svedstr&ouml;m E. Magnetic resonance imaging in pediatric elbow fractures. Acta Radiol 2005; 46:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/24\">",
"      Marzo JM, d'Amato C, Strong M, Gillespie R. Usefulness and accuracy of arthrography in management of lateral humeral condyle fractures in children. J Pediatr Orthop 1990; 10:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19607/abstract/25\">",
"      Blane CE, Kling TF Jr, Andrews JC, et al. Arthrography in the posttraumatic elbow in children. AJR Am J Roentgenol 1984; 143:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6537 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19607=[""].join("\n");
var outline_f19_9_19607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Elbow joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ossification centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Growth plate (physis)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vascular anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nerve anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PLAIN RADIOGRAPHIC VIEWS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PLAIN RADIOGRAPH INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Normal ossification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Anterior humeral line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radial head alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fat pads",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Anterior fat pad",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Posterior fat pad",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Carrying angle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FURTHER IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Arthrography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Interpreting elbow radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6537\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6537|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/4/29760\" title=\"diagnostic image 1\">",
"      Normal lateral elbow radiograph child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/2/23586\" title=\"diagnostic image 2\">",
"      Normal AP and lateral elbow radiograph child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/7/25712\" title=\"diagnostic image 3\">",
"      Abnormal lateral elbow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/32/43534\" title=\"diagnostic image 4\">",
"      Monteggia fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/16/23823\" title=\"diagnostic image 5\">",
"      Type I supracondylar fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/32/31233\" title=\"diagnostic image 6\">",
"      Cubitus valgus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6537|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/29/37330\" title=\"figure 1\">",
"      Elbow joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/58/41903\" title=\"figure 2\">",
"      Elbow fat pads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/53/43858\" title=\"figure 3A\">",
"      Elbow ossification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/1/33809\" title=\"figure 3B\">",
"      Elbow fusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26918\" title=\"figure 4\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/52/23365\" title=\"figure 5\">",
"      Major arteries and nerves of the anterior elbow region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/33/21009\" title=\"figure 6\">",
"      Elbow radiograph position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/58/17313\" title=\"figure 7\">",
"      CRITOE mnemonic for elbow ossification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/7/20595\" title=\"figure 8\">",
"      Fat pad sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/52/18255\" title=\"figure 9\">",
"      Cubitus varus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/14/18671\" title=\"figure 10\">",
"      Baumann angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/61/36830\" title=\"figure 11\">",
"      Humeral ulnar angle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6537|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/19/12604\" title=\"table 1\">",
"      Skeletal maturity timeframe",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22663?source=related_link\">",
"      Epicondylar and transphyseal elbow fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19175?source=related_link\">",
"      Evaluation and management of condylar elbow fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=related_link\">",
"      Evaluation and management of supracondylar fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/35/20018?source=related_link\">",
"      Patient information: Elbow fracture in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_9_19608="DIP histology";
var content_f19_9_19608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Desquamative interstitial pneumonia pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The alveolar spaces are diffusely involved by marked alveolar macrophage accumulation and there is mild interstitial thickening. (B) The alveolar walls are mildly thickened by fibrous connective tissue and a few chronic inflammatory cells. The alveolar spaces are filled with macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19608=[""].join("\n");
var outline_f19_9_19608=null;
var title_f19_9_19609="Clinical manifestations and diagnosis of chronic myeloid leukemia";
var content_f19_9_19609=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of chronic myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19609/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19609/contributors\">",
"     Richard A Van Etten, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19609/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19609/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19609/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19609/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/9/19609/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML, also known as chronic myelocytic, chronic myelogenous, or chronic granulocytic leukemia) is a myeloproliferative neoplasm characterized by the dysregulated production and uncontrolled proliferation of mature and maturing granulocytes with fairly normal differentiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CML is associated with the fusion of two genes: BCR (on chromosome 22) and ABL1 (on chromosome 9) resulting in the BCR-ABL1 fusion gene. This abnormal fusion typically results from a reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34;q11), that gives rise to an abnormal chromosome 22 called the Philadelphia (Ph) chromosome. It is this derivative chromosome 22 which harbors the BCR-ABL1 fusion gene.",
"   </p>",
"   <p>",
"    The BCR-ABL1 fusion gene results in the formation of a unique gene product, the BCR-ABL1 fusion protein. This protein product includes an enzymatic domain from the normal ABL1 with tyrosine kinase catalytic activity, but relative to ABL1, whose kinase activity is tightly regulated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/1\">",
"     1",
"    </a>",
"    ], the kinase activity of BCR-ABL1 is elevated and constitutive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/2\">",
"     2",
"    </a>",
"    ] due to fusion with a portion of BCR. It is this deregulated tyrosine kinase that is implicated in the pathogenesis of CML. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical hallmark of CML is the uncontrolled production of mature and maturing granulocytes, predominantly neutrophils, but also basophils and eosinophils. In the absence of treatment, CML has a triphasic or biphasic clinical course as it progresses from a chronic phase to an accelerated phase and on to a terminal blast crisis. Sometimes it goes from chronic phase directly to blast crisis, particularly when the blast phase is lymphoid.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of CML will be reviewed here. The molecular genetics, biology, and treatment of this disorder are considered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CML accounts for approximately 15 to 20 percent of leukemias in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/3\">",
"     3",
"    </a>",
"    ]. It has an annual incidence of 1 to 2 cases per 100,000, with a slight male predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The median age at presentation is approximately 50 years for patients enrolled on clinical studies, but the actual median age from cancer registry data may be 10 years older. Exposure to ionizing radiation is the only known risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there is no known familial disposition to CML, rare families in which multiple members develop MPNs, including CML, have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/8\">",
"     8",
"    </a>",
"    ]. Studies of these families suggest the presence of an autosomal dominant mutation that may predispose to acquisition of a secondary somatic mutation such as the Ph chromosome translocation or JAK2 mutation. It is unknown whether specific genetic variants predispose persons in the general population to develop CML. However, a genome-wide association study of Korean and European cohorts suggested that persons with genetic variants at two chromosomal loci, 6q25.1 and 17p11.1, may be more likely to develop CML [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H25#H25\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'Familial PV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of CML is steadily increasing in the Western world, due to the dramatic effect of ABL1 kinase inhibitors on survival. It is estimated that there will be &gt;180,000 patients living with CML in the US by the year 2050 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CML has a triphasic or biphasic clinical course: a chronic phase, which is present at the time of diagnosis in approximately 85 percent of patients; an accelerated phase, in which neutrophil differentiation becomes progressively impaired and leukocyte counts are more difficult to control with treatment; and blast crisis, a condition resembling acute leukemia in which myeloid or lymphoid blasts proliferate in an uncontrolled manner [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/6\">",
"     6",
"    </a>",
"    ]. The varying definitions of these disease phases are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Disease phase'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical findings at diagnosis of CML vary among reported series and also depend upon the stage of disease at diagnosis. Twenty to 50 percent of patients are asymptomatic, with the disease first being suspected from routine blood tests [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Among symptomatic patients, systemic symptoms such as fatigue (34 percent), malaise (3 percent), weight loss (20 percent), excessive sweating (15 percent), abdominal fullness (15 percent), and bleeding episodes due to platelet dysfunction (21 percent) are common [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal pain and discomfort may include left upper quadrant pain (sometimes referred to the left shoulder) and early satiety, due to the enlarged spleen with or without perisplenitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenic infarction. Tenderness over the lower sternum, due to an expanding bone marrow, is sometimes seen. Acute gouty arthritis may also present at this time, due to overproduction of uric acid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other frequent findings include splenomegaly (present in 48 and 76 percent in two series), anemia (45 and 62 percent), white blood cell count above",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    (52 and 72 percent), and platelet count above 600,000 to",
"    <span class=\"nowrap\">",
"     700,000/microL",
"    </span>",
"    (15 and 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Involvement of extramedullary tissues such as the lymph nodes, skin, and soft tissues is generally limited to patients with blast crisis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral smear typically demonstrates a leukocytosis with a median white count of approximately",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    (range 12 to",
"    <span class=\"nowrap\">",
"     1000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/12\">",
"     12",
"    </a>",
"    ]. The white blood cell differential typically shows virtually all cells of the neutrophilic series, from myeloblasts to mature neutrophils with peaks in the percent myelocytes and segmented neutrophils (",
"    <a class=\"graphic graphic_picture graphicRef56954 \" href=\"UTD.htm?12/48/13062\">",
"     picture 1",
"    </a>",
"    ). Blasts typically account for less than 2 percent. The presence of a greater percent of myelocytes than the more mature metamyelocytes (\"leukemic hiatus\" or \"myelocyte bulge\") is one of the classic findings in CML [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/13\">",
"     13",
"    </a>",
"    ]. The granulocytes of chronic phase are morphologically normal with no evidence of dysplasia, but dysplasia can develop in more advanced disease, and particularly in accelerated phase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of the peripheral blood smear\", section on 'Neutrophil series'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although morphologically normal, the neutrophils in CML are cytochemically abnormal. The cytochemical reaction called leukocyte (or neutrophil) alkaline phosphatase (LAP, or NAP) when scored is low. The low LAP score is useful in excluding a reactive leukocytosis or \"leukemoid reaction,\" typically due to infection, in which the score is typically elevated or normal. Low LAP activity was also classically used to exclude polycythemia vera (PV) in the differential diagnosis of CML, in which LAP activity is also often increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Absolute basophilia is a universal finding in the blood smears from CML patients, and absolute eosinophilia is seen in about 90 percent of cases. Absolute monocytosis",
"    <span class=\"nowrap\">",
"     (&gt;1000/microL)",
"    </span>",
"    is not uncommon, although the percentage of monocytes is typically low (&lt;3 percent) The occasional patients with CML who have an alternate breakpoint in chromosome 22, producing a p190 BCR-ABL1 fusion protein rather than the classic p210 BCR-ABL1 fusion protein, tend to have a more prominent monocytosis and a low",
"    <span class=\"nowrap\">",
"     neutrophil/monocyte",
"    </span>",
"    ratio in the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link&amp;anchor=H12#H12\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'BCR-ABL1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The platelet count can be normal or elevated. Platelet counts above",
"    <span class=\"nowrap\">",
"     600,000/microL",
"    </span>",
"    are seen in 15 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Low platelet counts or thrombocytopenia, if present at diagnosis, should make one reconsider other diagnostic possibilities, such as one of the myelodysplastic syndromes. A normochromic, normocytic anemia is seen in 45 to 60 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone marrow biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow aspiration and biopsy demonstrates granulocytic hyperplasia with a maturation pattern that reflects that seen in the peripheral smear (",
"    <a class=\"graphic graphic_picture graphicRef68724 \" href=\"UTD.htm?8/11/8375\">",
"     picture 2",
"    </a>",
"    ). Other non-specific bone marrow findings include an increase in reticulin fibrosis and vascularity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of angiogenesis inhibitors\", section on 'Vascular endothelial growth factor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is usually a widened area of immature neutrophils in the paratrabecular cuff and mature neutrophils are found in the intertrabecular areas. Erythroid islands are reduced in number and size. Small megakaryocytes with hypolobulated nuclei (so-called \"dwarf megakaryocytes\") are present. These are smaller than normal megakaryocytes, but not as small as dysplastic \"micromegakaryocytes.\" Markers of increased cell turnover are commonly noted with Pseudo-Gaucher cells and sea-blue histiocytes. Iron-laden macrophages are reduced or absent.",
"   </p>",
"   <p>",
"    The peripheral blood and bone marrow aspirate differential count are key components of determining the disease stage. In general, peripheral blood and bone marrow blasts between 10 and 19 percent are diagnostic of accelerated phase disease, while blasts over 20 percent are diagnostic of blast crisis. Additional criteria for accelerated phase are also described, and these are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Disease phase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for the Philadelphia chromosome (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"UTD.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    ), the BCR-ABL1 fusion gene or the fusion mRNA gene product (",
"    <a class=\"graphic graphic_figure graphicRef73543 \" href=\"UTD.htm?8/58/9134\">",
"     figure 2",
"    </a>",
"    ) is done by conventional cytogenetic analysis (karyotyping), fluorescence in situ hybridization (FISH) analysis, or by reverse transcription polymerase chain reaction (RT-PCR). Southern blot techniques to identify BCR-ABL1 gene rearrangements were used in the past, but are time consuming and no longer employed as a routine diagnostic test. Evaluating for BCR-ABL1 protein by Western blot analysis is also not typically done. All patients with CML have evidence of the Philadelphia chromosome (Ph) (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"UTD.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    ), the BCR-ABL1 fusion gene or its product, the BCR-ABL1 fusion mRNA (",
"    <a class=\"graphic graphic_figure graphicRef73543 \" href=\"UTD.htm?8/58/9134\">",
"     figure 2",
"    </a>",
"    ) by at least one of these tests [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of patients (90 to 95 percent) demonstrate the t(9;22)(q34;q11.2) reciprocal translocation that results in the Ph chromosome. Some of the remaining minority have variant translocations such as complex translocations involving other chromosome (eg, t(9;14;22)). The rest have cryptic translocations of 9q34 and 22q11.2 that cannot be identified by routine cytogenetics. These are referred to as \"Ph-negative\" and require FISH analysis to identify the BCR-ABL1 fusion gene, or RT-PCR to identify the BCR-ABL1 fusion mRNA.",
"   </p>",
"   <p>",
"    As an example, approximately 15 percent of patients in a large prospective study lacked the Ph chromosome by cytogenetic analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/11\">",
"     11",
"    </a>",
"    ]. However, about one-half of such patients had complex chromosomal rearrangements masking a t(9;22) translocation; another subset was Ph-negative by karyotype but had evidence of BCR-ABL1 gene fusion by metaphase or interphase FISH analysis or RT-PCR. The clinical features of both groups of these patients are very similar to those with typical Ph chromosome positive CML. In contrast, patients whose cells lack evidence of BCR-ABL1 gene fusion by FISH or RT-PCR do not have CML, but may have a related condition, such as a myelodysplastic syndrome or disease with overlapping",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    features. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are several distinct BCR-ABL1 fusion proteins generated from the chromosomal translocation or molecular fusion, depending upon the site of the breakpoint in the BCR gene on chromosome 22.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common abnormal BCR-ABL1 fusion transcript produced is from a breakpoint in exon 13 or exon 14 (alternatively called exon b2 or b3) in the BCR gene, fused to the ABL1 gene at exon a2. These are referred to as e13a2, e14a2 or alternatively as b2a2 or b3a2. These fusions result in a BCR-ABL1 protein with 210 kilodalton molecular mass which is referred to as the p210 BCR-ABL1 protein. This p210 BCR-ABL1 protein has increased and constitutively activated tyrosine kinase activity, as discussed above.",
"     </li>",
"     <li>",
"      Less commonly, an alternative e19a2 fusion transcript is found, producing a larger fusion protein with 230 kilodalton weight (p230 BCR-ABL1). This is seen in rare CML cases (&lt;1 percent).",
"     </li>",
"     <li>",
"      A smaller e1a2 fusion transcript, which produces the p190 BCR-ABL protein is also seen in a very small number of CML patients, but is more frequently associated with Ph-positive acute lymphoblastic leukemia (ALL). It is also often produced in small quantities by patients with the classic p210 transcript as a form of alternative splicing of the BCR gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All the BCR-ABL1 fusion proteins exhibit dysregulated tyrosine kinase activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link&amp;anchor=H4596194#H4596194\">",
"     \"Molecular genetics of chronic myeloid leukemia\", section on 'Distinct forms of BCR-ABL1 from alternative chromosome 22 breakpoints'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link&amp;anchor=H8#H8\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'The BCR-ABL1 fusion protein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the Philadelphia chromosome (Ph) translocation is the initiating event in CML, progression to accelerated phase or blast crisis appears to require the acquisition of other chromosomal or molecular changes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/6\">",
"     6",
"    </a>",
"    ]. Additional cytogenetic abnormalities develop in over 80 percent of patients in the accelerated and blast crisis phases, most commonly trisomy 8, trisomy 19, duplication of the Ph chromosome, and isochromosome 17q (leading to the loss of the P53 gene on 17p). These can be seen singly in addition to the Ph chromosome or in any combination. The evolution of any of these additional karyotypic findings confers a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/16\">",
"     16",
"    </a>",
"    ]. These additional cytogenetic aberrations may also be found at the time of diagnosis in approximately 7 percent of patients and are associated with a lower response rate to tyrosine kinase inhibitors and inferior survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=see_link&amp;anchor=H7228199#H7228199\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'Progression to acute phase CML'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CML is first suspected by identifying the typical findings in the blood and bone marrow, and then confirmed by the demonstration of the Philadelphia chromosome (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"UTD.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    ), the BCR-ABL1 fusion gene or the BCR-ABL1 fusion mRNA (",
"    <a class=\"graphic graphic_figure graphicRef73543 \" href=\"UTD.htm?8/58/9134\">",
"     figure 2",
"    </a>",
"    ) by conventional cytogenetics, fluorescence in situ hybridization (FISH) analysis, or reverse transcription polymerase chain reaction (RT-PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    can be used to reduce white blood cell counts while awaiting confirmation of a suspected diagnosis of CML in a patient with significant leukocytosis (eg, &gt;80 x10",
"    <sup>",
"     9",
"    </sup>",
"    white",
"    <span class=\"nowrap\">",
"     cells/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Other agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other disorders that resemble CML clinically. These include a leukemoid reaction, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, \"atypical CML\", chronic eosinophilic leukemia, chronic neutrophilic leukemia, other myeloproliferative neoplasms, and other Ph-positive leukemias. These are discussed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Leukemoid reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A leukemoid reaction describes a high leukocyte count with neutrophilia and prominent left shift, usually in response to infection. The peripheral blood count may be as high as",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and can easily mimic CML. However, the following features are more commonly found in a leukemoid reaction and help to distinguish it from CML: toxic granulation in the neutrophils, a high LAP score, lack of a \"myelocyte bulge\", and most importantly, the presence of an obvious cause for the neutrophilia. Bone marrow examination is often not helpful. Cytogenetic or molecular testing is definitive for CML if the distinction cannot be made clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Juvenile myelomonocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile myelomonocytic leukemia (JMML, formerly called \"juvenile CML\") is a rare fatal disorder of infancy and early childhood characterized by the combination of hepatosplenomegaly, lymphadenopathy, pallor, fever, and skin rash [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with JMML demonstrate clonal overproduction of maturing myeloid cells, usually with an excess of monocytic lineage cells that are hyper-responsive to granulocyte macrophage colony-stimulating factor (GM-CSF), leading to organ infiltration with relatively normal appearing monocytes and macrophages and death from organ failure or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In contrast to CML, the karyotype in JMML is normal or sometimes shows monosomy 7, and progression to acute leukemia is rare. Many patients with JMML have mutations in genes that encode elements of the GM-CSF signal transduction pathway, including PTPN11, NRAS and KRAS2, CBL, and NF1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is notable that children and infants can have typical CML. Because of the imprecise older term \"juvenile CML\" for JMML, it is important to clearly indicate if the case is truly CML by noting that it is \"BCR-ABL1 positive or Ph positive.\" The correct diagnosis will have important treatment implications and must be communicated unambiguously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronic myelomonocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myelomonocytic leukemia (CMML) is a",
"    <span class=\"nowrap\">",
"     myelodysplastic/myeloproliferative",
"    </span>",
"    neoplasm characterized by the overproduction of maturing monocytic cells and sometimes dysplastic neutrophils, often accompanied by anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/26\">",
"     26",
"    </a>",
"    ]. Unlike CML, the bone marrow morphology in CMML demonstrates prominent dysplastic changes in at least two of the three myeloid lineages (",
"    <a class=\"graphic graphic_table graphicRef55582 \" href=\"UTD.htm?1/4/1100\">",
"     table 1",
"    </a>",
"    ). In addition, genetic testing does not demonstrate evidence of BCR-ABL1, the Ph chromosome or their products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H359854#H359854\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'WHO Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     \"Atypical CML\"",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Atypical CML\" is a",
"    <span class=\"nowrap\">",
"     myelodysplastic/myeloproliferative",
"    </span>",
"    neoplasm that is characterized by features of dysplasia and of myeloid proliferation at the same time. The entity is uncommon, but can cause a considerable diagnostic challenge. Patients are elderly and present with high neutrophil counts but with thrombocytopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia. The bone marrow shows increased cellularity due to a granulocytic proliferation without increased blasts. There is no monocytosis in the blood or marrow. The distinguishing feature of \"atypical CML\" is the presence of dysplasia in the neutrophils, and sometimes in the megakaryocytes and erythroid forms as well [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Atypical CML\" is an unfortunate term for this disorder since it is NOT a type of CML that is \"atypical.\" It is BCR-ABL1-negative and Ph-negative, a finding that should be noted in the diagnosis to avoid confusion. Atypical CML can be associated with other cytogenetic changes including trisomy 8, and isochromosome 17q [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/28\">",
"     28",
"    </a>",
"    ]. In one study, recurrent somatic point mutations of set-binding protein 1 (SETBP1) were identified in 17 of 70 (24 percent) cases of atypical CML; a smaller percentage of cases of myelodysplastic",
"    <span class=\"nowrap\">",
"     syndrome/myeloproliferative",
"    </span>",
"    disorder, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia; and none of 458 individuals with other hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of patients with atypical CML is poor, and transformation to AML can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic eosinophilic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic eosinophilic leukemia (CEL) is a rare clonal chronic myeloproliferative disorder characterized by the overproduction of normal appearing eosinophils in the bone marrow with proliferation in the blood and infiltration into the organs resulting in end organ damage. There is only a minor tendency to progress to acute myeloid leukemia (AML) (",
"    <a class=\"graphic graphic_table graphicRef54770 \" href=\"UTD.htm?39/44/40652\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/30\">",
"     30",
"    </a>",
"    ]. Cytogenetics in CEL may be normal or exhibit clonal abnormalities including del(4q12), rearrangement of 5q22, 12p16, or 8p11. Molecularly, some cases have rearrangements involving the tyrosine kinases PDGFRA, PDGFRB or ETV6 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Cases of CEL do not demonstrate the Ph chromosome or BCR-ABL1 gene fusion. However, some cases do respond to imatinib therapy since the underlying molecular pathogenesis is related to overactivity of an imatinib-sensitive tyrosine kinase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Diagnosis of myeloproliferative variants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic neutrophilic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic neutrophilic leukemia (CNL) is a rare disorder characterized by mature granulocytic proliferation in the blood and marrow, and infiltration into the organs resulting in hepatosplenomegaly. There is often toxic granulation in the neutrophils, nuclear hypersegmentation and an increased leukocyte alkaline phosphatase (LAP) score (",
"    <a class=\"graphic graphic_table graphicRef75777 \" href=\"UTD.htm?5/9/5276\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. The Ph chromosome and its products are not detected in patients with chronic neutrophilic leukemia. Although these patients do not usually progress to AML, their survival is short and usually less than two years. Effective treatment is uncertain; some patients have responded to interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is notable that some patients with myeloma or other immunoproliferative disease with increased plasma cells can have marked neutrophilia. This may be due to the secretion of neutrophil-stimulating cytokines from the plasma cells. Such cases likely represent reactive neutrophilia and not CNL. True cases of CNL should have clonal neutrophils that might be demonstrated by a cytogenetic clone or by clonality studies such as the HUMARA analysis.",
"   </p>",
"   <p>",
"    Lastly, rare cases of CML have a p230 BCR-ABL1, and these may be associated with either a prominent neutrophil proliferation or a prominent thrombocytosis. The former (sometime referred to as \"CML-N\") may be particularly difficult to distinguish from CNL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other myeloproliferative neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of patients present with clinical characteristics of one of the other myeloproliferative neoplasms (eg, essential thrombocythemia or polycythemia vera) but are Ph-positive by cytogenetic analysis. The majority of these patients exhibits a clinical course consistent with CML, including eventual progression to blast crisis, and must be considered CML with an atypical initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/37\">",
"     37",
"    </a>",
"    ]. The typical non-CML myeloproliferative neoplasms (polycythemia vera, essential thrombocytosis, and primary myelofibrosis) are BCR-ABL1-negative and Ph-chromosome-negative, and will not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    Sensitive reverse transcriptase-polymerase chain reaction (RT-PCR) assays for detection of the BCR-ABL1 fusion mRNA have shown that this product can be detected at low levels in approximately 50 percent of Ph-negative patients with ET; these individuals do not have a clinical course that is distinctly different from classical ET [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/38\">",
"     38",
"    </a>",
"    ], and should not be considered CML. The significance of BCR-ABL1 transcripts in this setting requires further investigation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the clinical course and initial blood findings of patients with the other myeloproliferative neoplasms can sometimes overlap with those of CML, the bone marrow evaluation can be helpful in distinguishing them apart. CML has small \"dwarf\" megakaryocytes, and the other myeloproliferative neoplasms typically have large atypical megakaryocytes. Evaluation for the Ph-chromosome by cytogenetics, BCR-ABL1 by FISH or high levels of BCR-ABL1 transcripts by RT-PCR will usually resolve any difficult cases.",
"   </p>",
"   <p>",
"    Rare cases have been reported with JAK2 V617F mutations, commonly seen in the non-CML myeloproliferative neoplasms, which go on to develop the Ph-chromosome and BCR-ABL1 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/39\">",
"     39",
"    </a>",
"    ]. These are quite unusual and are likely cases of non-CML MPN which develop superimposed CML. The opposite sequence of events has also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other Philadelphia chromosome-positive malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ph chromosome is found in 20 to 30 percent of adults with acute precursor B-cell lymphoblastic leukemia (ALL), 5 to 10 percent of childhood ALL, and about 1 percent of adult AML [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients with Ph-positive acute leukemia are heterogeneous when analyzed at the molecular level. At least some of these patients probably represent CML presenting in blast crisis phase, but others may represent de novo acute leukemia.",
"   </p>",
"   <p>",
"    Often one can identify the blastic disease and recognize CML in the background in patients who have CML that is presenting in blasts crisis. For example, a patient might present with a WBC of",
"    <span class=\"nowrap\">",
"     600,000/microL",
"    </span>",
"    and have 60 percent lymphoblasts, but 40 percent of the cells",
"    <span class=\"nowrap\">",
"     (240,000/microL)",
"    </span>",
"    are immature with maturing neutrophils, a \"myelocyte bulge,\" and basophilia. This is clearly CML with a lymphoid blast crisis superimposed. In such a case the Ph chromosome will be in the lymphoblasts and in the neutrophils, whereas in Ph+ ALL the clone is restricted to the lymphoid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Ph chromosome has been reported rarely in other hematological malignancies, including multiple myeloma and B-cell non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link&amp;anchor=H6#H6\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\", section on '9;22 translocation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to identify patients at diagnosis who have an unfavorable prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/44-51\">",
"     44-51",
"    </a>",
"    ]. By far the strongest single predictor of outcome in patients with CML is the stage of disease at the time of diagnosis. Patients with chronic phase at the time of diagnosis can have years of disease control with treatment while those in accelerated phase or blast crisis have a much poorer prognosis.",
"   </p>",
"   <p>",
"    This observation also holds for the subgroup of patients harboring the BCR-ABL T315I mutation, which is resistant to all of the currently available tyrosine kinase inhibitors. In a study of 222 such patients, median overall survival was 22, 28, 4, and 5 months when this mutation was detected during chronic phase, accelerated phase, blast phase, or Ph+ ALL, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Scoring systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various scoring systems have also been devised in an attempt to predict disease outcome (",
"    <a class=\"graphic graphic_table graphicRef60446 \" href=\"UTD.htm?23/9/23709\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Sokal prognostic score, for example, identified four clinical variables: spleen size, percent blasts, age, and platelet count",
"      <span class=\"nowrap\">",
"       &gt;700,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/44\">",
"       44",
"      </a>",
"      ]. The first three behaved as continuous variables with progressively worse prognosis at higher values. An online calculator for the Sokal score is available for this purpose [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Hasford or Euro score, which adds eosinophilia and basophilia to the calculation, was developed for CML patients receiving treatment with interferon and appears to behave in a similar manner (",
"      <a class=\"external\" href=\"file://www.leukemia-net.org/content/leukemias/cml/cml_score/\">",
"       Euro score calculator",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/45,49\">",
"       45,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While the Sokal and Euro (Hasford) scores were developed prior to the discovery of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , the EUTOS score was developed and validated using data from 2060 patients enrolled in prospective studies of imatinib [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/53\">",
"       53",
"      </a>",
"      ], and is intended to be a better predictor of clinical responses to that drug. The EUTOS score is substantially simpler than either Sokal or Hasford scores and is based only on the percentage of basophils and spleen size (",
"      <a class=\"external\" href=\"file://www.leukemia-net.org/content/leukemias/cml/eutos_score/\">",
"       EUTOS score calculator",
"      </a>",
"      ). Patients could be divided into low and high risk groups with rates of progression-free survival after treatment with imatinib at five years of 90 and 82 percent, respectively. This new score requires only two variables and has a higher predictive power than either the Sokal or Euro scores. High-risk patients defined by this scoring system have a one in three chance of failing to respond to imatinib. This prognostic index has not yet been widely utilized to stratify patients in clinical trials in CML, and it remains to be seen whether EUTOS will be applicable to patients on more potent second generation TKIs like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19609/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These scoring systems provide useful prognostic information for CML patients treated with ABL kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    mesylate, as the probability of achieving a complete cytogenetic remission is significantly lower in high-risk patients. However, once a cytogenetic remission is obtained, patients in all risk categories have an excellent prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/58/12194?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML) is suspected in a patient with some or all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic complaints (fatigue, malaise, sweating, weight loss).",
"     </li>",
"     <li>",
"      Early satiety",
"     </li>",
"     <li>",
"      Tenderness over the lower sternum",
"     </li>",
"     <li>",
"      Varying degrees of hepatosplenomegaly",
"     </li>",
"     <li>",
"      Laboratory findings of an elevated white blood cell count with a peripheral smear demonstrating increased numbers of immature cells of the granulocytic series with a \"myelocyte bulge\" associated with mild anemia, thrombocytosis, and basophilia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the diagnosis can be made fairly accurately by morphologic features in the blood and marrow, the \"gold standard\" for the diagnosis of CML is either the demonstration of the Philadelphia chromosome or the underlying t(9;22) translocation by conventional cytogenetic techniques (",
"    <a class=\"graphic graphic_figure graphicRef62227 \" href=\"UTD.htm?16/20/16719\">",
"     figure 1",
"    </a>",
"    ), or the demonstration of the BCR-ABL1 fusion gene or mRNA fusion product (",
"    <a class=\"graphic graphic_figure graphicRef73543 \" href=\"UTD.htm?8/58/9134\">",
"     figure 2",
"    </a>",
"    ) by fluorescence in situ hybridization (FISH) analysis, or reverse transcription polymerase chain reaction (RT-PCR).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/1\">",
"      Van Etten RA. c-Abl regulation: a tail of two lipids. Curr Biol 2003; 13:R608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/2\">",
"      Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5:3116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/4\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/5\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/6\">",
"      Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/7\">",
"      Moloney WC. Radiogenic leukemia revisited. Blood 1987; 70:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/8\">",
"      Bellann&eacute;-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/9\">",
"      Kim DH, Lee ST, Won HH, et al. A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood 2011; 117:6906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/10\">",
"      Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012; 118:3123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/11\">",
"      Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997; 96:111.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/13\">",
"      Spiers AS, Bain BJ, Turner JE. The peripheral blood in chronic granulocytic leukaemia. Study of 50 untreated Philadelphia-positive cases. Scand J Haematol 1977; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/14\">",
"      Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/15\">",
"      Ravandi F, Cortes J, Albitar M, et al. Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance. Br J Haematol 1999; 107:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/16\">",
"      Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101:3794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/17\">",
"      Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118:6760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/18\">",
"      Niemeyer CM, Kratz C. Juvenile myelomonocytic leukemia. Curr Oncol Rep 2003; 5:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/19\">",
"      Koike K, Matsuda K. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia. Br J Haematol 2008; 141:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/20\">",
"      Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008; 22:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/21\">",
"      Aric&ograve; M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997; 90:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/22\">",
"      Passmore SJ, Chessells JM, Kempski H, et al. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003; 121:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/23\">",
"      Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/24\">",
"      De Filippi P, Zecca M, Lisini D, et al. Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol 2009; 147:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/25\">",
"      Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010; 42:794.",
"     </a>",
"    </li>",
"    <li>",
"     Vardiman JW, Pierre R, Bain B, et al. Chronic myelomonocytic leukemia. In: World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.49.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/27\">",
"      Hern&aacute;ndez JM, del Ca&ntilde;izo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000; 11:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/28\">",
"      McClure RF, Dewald GW, Hoyer JD, Hanson CA. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 1999; 106:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/29\">",
"      Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/30\">",
"      Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996; 95:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/31\">",
"      Oliver JW, Deol I, Morgan DL, Tonk VS. Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet 1998; 107:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/32\">",
"      Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol 2003; 122:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/33\">",
"      Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/34\">",
"      Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol 2002; 116:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/35\">",
"      Elliott MA. Chronic neutrophilic leukemia: a contemporary review. Curr Hematol Rep 2004; 3:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/36\">",
"      B&ouml;hm J, Schaefer HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol 2002; 55:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/37\">",
"      Stoll DB, Peterson P, Exten R, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol 1988; 27:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/38\">",
"      Blickstein D, Aviram A, Luboshitz J, et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation. Blood 1997; 90:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/39\">",
"      Kr&auml;mer A. JAK2-V617F and BCR-ABL--double jeopardy? Leuk Res 2008; 32:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/40\">",
"      Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/41\">",
"      Anastasi J, Feng J, Dickstein JI, et al. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia. Leukemia 1996; 10:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/42\">",
"      Martiat P, Mecucci C, Nizet Y, et al. P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma. Leukemia 1990; 4:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/43\">",
"      Mitani K, Sato Y, Tojo A, et al. Philadelphia chromosome positive B-cell type malignant lymphoma expressing an aberrant 190 kDa bcr-abl protein. Br J Haematol 1990; 76:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/44\">",
"      Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia. Blood 1984; 63:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/45\">",
"      Bonifazi F, De Vivo A, Rosti G, et al. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol 2000; 111:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/46\">",
"      Kvasnicka HM, Thiele J, Schmitt-Graeff A, et al. Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients. Br J Haematol 2001; 112:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/47\">",
"      Kvasnicka HM, Thiele J, Schmitt-Graeff A, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol 2001; 19:2994.",
"     </a>",
"    </li>",
"    <li>",
"     Sokal risk score calculator available online at: www.roc.se/sokal.asp (Accessed on February 19, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/49\">",
"      Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/50\">",
"      Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/51\">",
"      Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012; 120:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/52\">",
"      Nicolini FE, Mauro MJ, Martinelli G, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009; 114:5271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/53\">",
"      Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19609/abstract/54\">",
"      Jabbour E, Cortes J, Nazha A, et al. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 2012; 119:4524.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4543 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-346F7DA307-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19609=[""].join("\n");
var outline_f19_9_19609=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Leukemoid reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Juvenile myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronic myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      \"Atypical CML\"",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic eosinophilic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic neutrophilic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other Philadelphia chromosome-positive malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Scoring systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4543|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/20/16719\" title=\"figure 1\">",
"      The Philadelphia chromosome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/58/9134\" title=\"figure 2\">",
"      BCR-ABL FISH in CML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4543|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/48/13062\" title=\"picture 1\">",
"      CML blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/11/8375\" title=\"picture 2\">",
"      CML marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/4/1100\" title=\"table 1\">",
"      CMML criteria WHO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/44/40652\" title=\"table 2\">",
"      Chronic eosinophilic leukemia WHO criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5276\" title=\"table 3\">",
"      Chron neutrophilic leuk WHO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/9/23709\" title=\"table 4\">",
"      CML prognostic models",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=related_link\">",
"      Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/58/12194?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_9_19610="Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas";
var content_f19_9_19610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19610/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19610/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19610/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19610/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19610/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/9/19610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/9/19610/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/9/19610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1060690\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-Hodgkin lymphoma subtype of marginal zone lymphoma includes three distinct diseases that have been historically classified together because they appear to arise from post-germinal center marginal zone B cells and share a similar immunophenotype: positive for B cell markers CD19, CD20, and CD22, and negative for CD5, CD10, and usually CD23 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three diseases in this category that are recognized in the",
"    <span class=\"nowrap\">",
"     REAL/WHO",
"    </span>",
"    classification systems include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) type (MALT-type lymphoma, MALT lymphoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nodal marginal zone B cell lymphoma",
"     </li>",
"     <li>",
"      Splenic marginal zone B cell lymphoma (&plusmn; villous lymphocytes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no clinical overlap of extranodal MZL (MALT lymphoma) and nodal MZL with splenic MZL, despite the fact that splenic MZL may have a marginal zone pattern; these diseases appear to be completely unrelated. As such, we present them separately.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, pathology, and diagnosis of extranodal (MALT) and nodal marginal zone lymphoma will be discussed here. The evaluation of primary gastrointestinal lymphoma is presented separately. In addition, splenic marginal zone B cell lymphoma and primary cutaneous marginal zone lymphoma are discussed separately, as is the treatment of these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=see_link\">",
"     \"Treatment of marginal zone (MALT) lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link\">",
"     \"Primary cutaneous marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTRANODAL (MALT) MZL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal marginal zone B cell lymphoma, also called low grade B cell lymphoma of mucosa associated lymphoid tissue (MALT), is an extranodal lymphoma that arises in a number of epithelial tissues, including the stomach, salivary gland, lung, small bowel, thyroid, and elsewhere. It was originally often referred to as a \"pseudo-lymphoma\" because of its tendency to remain localized to the tissue of origin for long periods of time, but it is now appreciated that it is a clonal B cell neoplasm that frequently recurs locally and has potential for systematic spread and transformation to a high-grade B cell lymphoma. Extranodal MZL of the lung is sometimes referred to as bronchial-associated lymphoid tissue (BALT) lymphoma, while extranodal MZL of the skin may be referred to as skin-associated lymphoid tissue (SALT) lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal MZL constitutes about 5 percent of all non-Hodgkin lymphomas (",
"    <a class=\"graphic graphic_table graphicRef64113 \" href=\"UTD.htm?34/39/35453\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/5\">",
"     5",
"    </a>",
"    ], and almost 50 percent of all gastric lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In other sites, such as the ocular adnexa, they comprise up to 90 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], as well as the majority of low grade pulmonary lymphomas (eg, bronchial-associated lymphoid tissue [BALT] lymphoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. These are mainly tumors of adults; a slight female predominance has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The incidence of gastric MZL declined in the late 1990s, but has remained stable since 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal MZL is postulated to arise from post germinal center memory B cells with the capacity to differentiate into marginal zone cells, and plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/17\">",
"     17",
"    </a>",
"    ]. Four recurrent chromosomal translocations have been found:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      t(11;18) (q21;q21)",
"     </li>",
"     <li>",
"      t(14;18)(q32;q21)",
"     </li>",
"     <li>",
"      t(1;14)(p22;q32)",
"     </li>",
"     <li>",
"      t(3;14)(p13;q32)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In normal B and T cells, signals produced by the interaction of antigen with antigen receptors on the cell surface cause the protein B-cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    10 (BCL-10) to bind to the MALT lymphoma-associated translocation (MALT1) protein. This triggers additional events that result in the activation of NF-kappa B, a transcription factor that turns on a set of genes that promote B cell survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. The t(11;18), the t(14;18), and the t(1;14) translocations all result in pathophysiologic increases in the activation of NF-kappa B through the",
"    <span class=\"nowrap\">",
"     BCL-10/MALT1",
"    </span>",
"    signaling complex, and in doing so enhance the survival of extranodal MZL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specifically, the t(11;18) translocation fuses the apoptosis inhibitor-2 gene on chromosome 11 (variously called API2 or IAP2) with the MALT1 gene on chromosome 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The t(14;18)(q32;q21) fuses MALT1 with the IgH gene. The rare t(1;14)(p22;q32) fuses the coding sequence of BCL-10 on chromosome 1 to the IgH",
"    <span class=\"nowrap\">",
"     promoter/enhancer",
"    </span>",
"    elements [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/27\">",
"     27",
"    </a>",
"    ]. These all result in over-expression of BCL-10, which causes cellular transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/28\">",
"     28",
"    </a>",
"    ], and provides a survival advantage to the neoplastic B cells. Nuclear expression of BCL-10 or NF-kappa B in gastric MALT, determined by immunohistochemistry, is associated with resistance of gastric MZLs to antibiotic therapy, even in those tumors that lack the t(11;18) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other known translocation, t(3;14)(p13;q32), fuses the FOXP1 gene on chromosome 3 to the IgH gene and results in increased nuclear levels of the FOXP1 transcription factor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/30\">",
"     30",
"    </a>",
"    ]. Its function is not yet known, but one study found high nuclear FOXP1 to be linked to poor outcome in extranodal MZL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/31\">",
"     31",
"    </a>",
"    ]. Of further interest, tumors with FOXP1 translocation appear to transform to diffuse large B cell lymphoma frequently, whereas those with the t(11;18) do so rarely, if ever [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increasing evidence suggests that extranodal MZL may be related to chronic immune stimulation, often due to bacterial or autoimmune stimuli. The prototypical example is the association of H. pylori infection with chronic gastritis and the development of gastric MALT. The association of extranodal MZL with autoimmune diseases and infectious agents is presented in more detail below. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Disease associations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One suggested pathogenic mechanism in extranodal MZL is that chronic inflammation leads to the local accumulation and proliferation of antigen-dependent B cells and T cells. With time, B cell clones that still depend on antigen for growth and survival, bearing still unknown mutations, emerge. At this stage, the proliferation is monoclonal (and thus a tumor), but not yet able to spread beyond the site of inflammation. With acquisition of additional mutations, including the chromosome abnormalities cited above, the tumor becomes antigen-independent and capable of systemic spread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of extranodal MZL differs depending upon the tissue involved. Patients can present with symptoms of peptic ulcer disease, abdominal pain,",
"    <span class=\"nowrap\">",
"     sicca/Sj&ouml;gren's",
"    </span>",
"    syndrome, or with a mass at the site of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The majority present with localized stage I or II extranodal disease, involving glandular epithelial tissues of various sites.",
"   </p>",
"   <p>",
"    The stomach is the most frequent site of involvement (",
"    <a class=\"graphic graphic_picture graphicRef81847 \" href=\"UTD.htm?30/41/31376\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70267 \" href=\"UTD.htm?9/12/9422\">",
"     picture 2",
"    </a>",
"    ), but this tumor can involve the lung, thyroid, breast, synovium, lacrimal and salivary glands, orbit, dura, skin, and soft tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/10,33-43\">",
"     10,33-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link\">",
"     \"Primary cutaneous marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These lymphomas disseminate to other MALT sites, lymph nodes, or marrow in about 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/14\">",
"     14",
"    </a>",
"    ]. It had been thought that this was often a late event. However, increasing evidence suggests that disease may often be disseminated at diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of 158 patients found disseminated disease in 54 (34 percent) at diagnosis; 17 of these patients had multiple involved mucosal sites [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 36 patients presenting with nongastrointestinal MALT lymphoma (eg, salivary gland, ocular adnexa, lung, oral cavity), 12 (33 percent) were found to have gastric involvement at the time of initial workup [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of these and similar studies suggest that routine evaluation of the stomach should be a part of the initial staging workup, and at relapse, of most non-GI MALT lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peripheral blood is usually not initially involved; however, some series report lymph node or bone marrow involvement in up to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/44\">",
"     44",
"    </a>",
"    ]. Our own clinical experience suggests that this occurs less frequently. Systemic \"B symptoms\" are uncommon. A monoclonal gammopathy has been found in 27 to 36 percent of patients with extranodal MZL, and has been correlated with plasmacytic differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/48\">",
"     48",
"    </a>",
"    ] as well as with advanced disease, including involvement of lymph nodes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing evidence suggests that MALT lymphoma is related to chronic immune reactions driven by bacterial, viral, or autoimmune stimuli. Proliferation of the cells of MZL at certain sites appears to depend on the presence of activated, antigen-driven T cells. As such, patients with MALT may also display evidence of the diseases described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Autoimmune disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with MALT have a history of autoimmune disease (eg, Sj&ouml;gren's syndrome, relapsing polychondritis, Hashimoto's thyroiditis) with or without coexisting infections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/33,50-52\">",
"     33,50-52",
"    </a>",
"    ]. \"Acquired MALT\" tissue secondary to autoimmune disease or infection in these sites is thought to be the substrate for lymphoma development [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Specifics on the various autoimmune disorders are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of relapsing polychondritis\", section on 'Eye involvement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link&amp;anchor=H12#H12\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\", section on 'Gastric lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Gastric MALT lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H5#H5\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overwhelming body of evidence has shown that the development of MALT lymphomas (also called MALTomas) is due to the clonal expansion of B cells that accompanies chronic gastritis in the presence of Helicobacter pylori. H pylori-induced gastritis first leads to the accumulation of CD4+ lymphocytes and mature B cells in the gastric lamina propria. Antigens derived from H pylori drive the activation of T cells, B cell proliferation, and lymphoid follicle formation, which if persistent can evolve into a monoclonal lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy directed at the H pylori infection results in regression of most",
"    <strong>",
"     early",
"    </strong>",
"    lesions and has become the treatment of choice for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Most patients (&gt;90 percent) with gastric MALT lymphoma are H pylori positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link&amp;anchor=H12#H12\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\", section on 'Gastric lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Borrelia afzelii",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is controversy regarding a possible link between solitary cutaneous marginal zone lymphoma and Borrelia afzelii infection, a species of Borrelia burgdorferi associated with Lyme disease almost exclusively found in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=see_link\">",
"     \"Epidemiology of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies suggest that treatment with antibiotic therapy may cure a proportion of patients with B. afzelii-associated cutaneous lymphoma. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link&amp;anchor=H3#H3\">",
"     \"Primary cutaneous marginal zone lymphoma\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chlamydophila (Chlamydia) psittaci",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between psittacosis and ocular adnexal marginal zone lymphoma (OAL) has been described, suggesting that Chlamydophila psittaci may be a causative agent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. There are conflicting reports of this association across geographic regions and in studies from the same regions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Antibiotics have shown variable efficacy against OAL . The use of antibiotics in OAL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of marginal zone (MALT) lymphoma\", section on 'Limited (stage I-II) disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the evidence supporting this association comes from Italy where OAL has been associated with Chlamydophila (formerly Chlamydia) psittaci infection in 80 percent of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/54,65\">",
"     54,65",
"    </a>",
"    ]. Treatment of Chlamydophila infection with the antibiotic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    has produced tumor response in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. However, this organism was not seen in any tumor specimens from a number of other countries, including Japan, France, the Netherlands, and the United States, and in only 2 of 26 cases from Cuba [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/10,70-73\">",
"     10,70-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of available reports indicates striking variability in the association between this infection and OAL across geographic regions, as well as variability in its response to treatment with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Campylobacter jejuni",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoproliferative small intestinal disease (IPSID, Mediterranean lymphoma, alpha heavy chain disease) is a variant of extranodal MZL that primarily occurs in young adults in the Middle East, North and South Africa, and the Far East [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/74\">",
"     74",
"    </a>",
"    ]. Clinical features include intermittent diarrhea, colicky abdominal pain, and symptoms related to malabsorption. Upper endoscopy usually shows diffuse abnormalities from the second part of the duodenum through the upper jejunum consisting of thickening, erythema, and nodularity of the mucosal folds. Biopsy shows an infiltrate of centrocyte-like cells and plasma cells. An alpha heavy chain protein without an associated light chain may be detected in the serum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=see_link&amp;anchor=H9#H9\">",
"     \"The heavy chain diseases\", section on 'Alpha HCD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational studies suggest an association with Campylobacter jejuni infection and there have been some reports of responses to antibiotics directed at this infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/53,75,76\">",
"     53,75,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\", section on 'Lymphoma of the small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal MZL reproduces the morphologic features of normal mucosa associated lymphoid tissue (MALT). It is characterized by a polymorphous infiltrate of small lymphocytes, marginal zone (centrocyte-like) B cells, monocytoid B cells, and plasma cells, as well as less frequent large activated cells (centroblast- or immunoblast-like) (",
"    <a class=\"graphic graphic_picture graphicRef68386 \" href=\"UTD.htm?22/1/22552\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59651 \" href=\"UTD.htm?14/62/15335\">",
"     picture 4",
"    </a>",
"    ). Reactive follicles are usually present, with the neoplastic marginal zone or monocytoid B cells occupying the marginal zone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the interfollicular region. Occasional follicles may be \"colonized\" by marginal zone or monocytoid cells. In tissues with epithelial linings, the tumor cells typically infiltrate the epithelium, forming so-called lymphoepithelial lesions (",
"    <a class=\"graphic graphic_table graphicRef78881 \" href=\"UTD.htm?38/25/39323\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/77\">",
"     77",
"    </a>",
"    ]. While large cells are typically present, they are by definition in the minority.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor cells express surface membrane immunoglobulin (IgM&gt;IgG&gt;IgA) and lack IgD; 40 to 60 percent have monotypic cytoplasmic immunoglobulin, indicating plasmacytic differentiation. They express B cell-associated antigens (CD19, CD20, CD22, CD79a) (",
"    <a class=\"graphic graphic_picture graphicRef59651 \" href=\"UTD.htm?14/62/15335\">",
"     picture 4",
"    </a>",
"    ) and complement receptors (CD21 and CD35), and are usually negative for CD5, CD10, and CD23 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunophenotyping studies are useful in confirming malignancy (light chain restriction) and in excluding",
"    <span class=\"nowrap\">",
"     B-CLL/SLL",
"    </span>",
"    and mantle cell lymphoma (which are CD5+) and follicular lymphomas (which are CD10+ CD43-, CD11c-, and usually cytoplasmic Ig-) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/13,79\">",
"     13,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Immunoglobulin gene rearrangement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoglobulin genes are rearranged, and the variable region has a high degree of somatic mutation, as well as intraclonal diversity, consistent with a post-germinal center stage of B cell development [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. The rearranged immunoglobulin heavy chain variable segments are often those that produce autoantibodies, consistent with prior studies showing that the antibodies produced by the tumor cells have specificity against self-antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/80\">",
"     80",
"    </a>",
"    ]. The BCL-1 (cyclin D1) and BCL-2 genes are not rearranged [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chromosomal abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosomal abnormalities are common in extranodal MZL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. The most commonly reported findings are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trisomy 3 (60 percent)",
"     </li>",
"     <li>",
"      t(11;18) (q21;q21) (25 to 40 percent)",
"     </li>",
"     <li>",
"      t(14;18)(q32;q21)",
"     </li>",
"     <li>",
"      t(1;14)(p22;q32)",
"     </li>",
"     <li>",
"      t(3;14)(p13;q32)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other chromosomal abnormalities have also been reported in extranodal MZL, including isochromosome 17q and 2p11 translocations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/88-91\">",
"     88-91",
"    </a>",
"    ], which are presently of uncertain pathogenic significance.",
"   </p>",
"   <p>",
"    Chromosomal studies may be useful for identifying subgroups of patients who may or may not respond to treatment. Some studies suggest that t(11;18) may characterize a subgroup of low-grade extranodal MALT lymphomas that are less likely to transform to high grade lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. In addition, a number of observations suggest that the presence of trisomy 3, a BCL-10 gene mutation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    t(11;18) might identify those patients with low-grade gastric MALT lymphomas who are less likely to benefit from anti-Helicobacter pylori treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/94-103\">",
"     94-103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of gastrointestinal lymphomas\", section on 'H pylori eradication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of extranodal (MALT) MZL is made based upon morphologic, immunophenotypic, and genetic analysis of biopsy material taken from an effected site.",
"   </p>",
"   <p>",
"    As described in more detail above, morphologic review reveals a polymorphous infiltrate of small cells with reactive follicles. While large cells are typically present, they are by definition in the minority. On immunophenotype, cells are positive for B cell markers CD19, CD20, and CD22, and negative for CD5, CD10, and CD23. Detection of a monoclonal immunoglobulin by flow cytometry or immunohistochemistry is helpful in confirming the neoplastic nature of the proliferation. Molecular diagnostic analysis consisting of PCR-based analysis of IgH gene rearrangements can also be very helpful in distinguishing extranodal MZL from reactive proliferations. Chromosomal abnormalities, usually trisomy 3 or t(11;18), are found in almost all cases and can be diagnostically helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Diffuse large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation between extranodal (MALT) MZL and diffuse large B cell lymphoma (DLBCL) is made primarily based upon morphologic features. Large clusters or sheets of large cells sufficient to warrant a diagnosis of large cell lymphoma are associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/6\">",
"     6",
"    </a>",
"    ]. These tumors are cytogenetically, biologically, and clinically different from extranodal MZL, and should be given a diagnosis of diffuse large B cell lymphoma. In addition, the term \"high grade MALT lymphoma\" should be avoided for large B cell lymphomas in MALT sites, since it may lead to inappropriate under-treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/2,104,105\">",
"     2,104,105",
"    </a>",
"    ]. Interestingly, neither trisomy 3 nor t(11;18) (q21;q21) is common in primary large cell lymphomas of the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/85,106\">",
"     85,106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Diffuse large B cell lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Small lymphocytic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small lymphocytic lymphoma (SLL), the solid tumor variant of the more common B cell CLL is composed of small lymphocytes on morphologic review. Immunophenotypically SLL co-express CD5 and CD23 whereas extranodal MZL do not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both extranodal MZL and mantle cell lymphoma (MCL) are neoplasms of small to medium-sized B lymphocytes. In addition, both can involve the gastrointestinal tract. On immunophenotype, MCL expresses CD5 and cyclin D1, while extranodal MZL does not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactive follicles are usually present in extranodal MZL and occasionally these follicles may be \"colonized\" by marginal zone or monocytoid cells. Prominent follicles are also seen in follicular lymphoma; however, these two entities can usually be distinguished by immunophenotype. Follicular lymphoma is typically CD10+, BCL-6+, and CD43-, and only rarely demonstrates plasmacytic differentiation, which is seen in about 40 percent of MALT lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     NODAL MZL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodal MZL is a primary nodal lymphoma with features identical to lymph nodes involved by extranodal (MALT) lymphoma, but without evidence of extranodal disease. This tumor is postulated to have originated from nodal monocytoid or marginal zone B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodal MZL is a rare disorder, comprising 1 percent of the NHL cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/108\">",
"     108",
"    </a>",
"    ]. Median age has ranged from 54 to 63 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients are asymptomatic, although most present with stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    non-bulky nodal disease. Bone marrow is involved in 30 to 60 percent; rarely, the peripheral blood may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/5,109,110\">",
"     5,109,110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Morphologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most cases of MZL in the lymph nodes have an extranodal component on further evaluation, there are occasional cases that appear to be true nodal marginal zone lymphomas. Two morphologic types have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cases that resemble extranodal (MALT) lymphoma, which show aggregates of monocytoid B cells in a parafollicular, perivascular, and perisinusoidal distribution, and have preserved germinal centers and mantle zones. About 60 percent of these patients prove to have extranodal MZL lymphoma on staging or follow-up. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Extranodal (MALT) MZL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cases that more closely resemble splenic marginal zone lymphoma (SMZL), which have infiltrates of marginal zone cells surrounding reactive germinal centers, with attenuated mantle zones [",
"      <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/111\">",
"       111",
"      </a>",
"      ]. In the few reported cases, no association with underlying SMZL was found. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Immunophenotypic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cases that resemble splenic MZL are reported to express IgD and to lack CD5, CD23, CD43 and cyclin D1. Those that resemble MALT lymphoma are IgD- and have an immunophenotype identical to those of extranodal (MALT) MZL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nodal MZL is made based upon nodal biopsy evaluation in the context of the clinical presentation. This diagnosis should not be made in patients with extranodal (MALT) lymphoma at other sites, Sj&ouml;gren's syndrome, or when another low-grade B cell lymphoma (follicular lymphoma, mantle cell lymphoma) is present in the same node.",
"   </p>",
"   <p>",
"    Tumors with morphologic features identical to those described for extranodal MZL (MALT-type) have occasionally been reported with isolated or disseminated nodal involvement, in the absence of extranodal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/4,112\">",
"     4,112",
"    </a>",
"    ]. Most reported cases of nodal monocytoid B cell lymphoma have been in patients with Sj&ouml;gren's syndrome, and thus represent nodal involvement by a MALT type lymphoma of the salivary gland [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Others have been reported as \"composite\" lymphomas with other histologically low-grade lymphomas, chiefly follicular lymphoma. In these cases, however, this phenomenon represents focal differentiation of a single lymphoma clone to marginal zone or monocytoid B cells, and is not a true composite lymphoma; these cases should be diagnosed as a single lymphoma (usually follicular lymphoma), and not as nodal MZL [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five-year overall survival in various series has ranged from 55 to 79 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/110,116-119\">",
"     110,116-119",
"    </a>",
"    ]. Prognostic factors are not well defined. In one study, a higher FLIPI (Follicular lymphoma international prognostic index) score predicted a worse overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?19/9/19610/abstract/110,120\">",
"     110,120",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H75814042#H75814042\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Follicular lymphoma IPI (FLIPI)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Extranodal (MALT) MZL",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extranodal marginal zone lymphoma (MZL) constitutes about 5 percent of all non-Hodgkin lymphomas. There is no age predilection for these tumors; a slight female predominance has been reported. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extranodal MZL is postulated to arise from post germinal center memory B cells. Several translocations resulting in increased activation of NF-kappa B have been implicated in the pathogenesis. These translocations can occur with or without a co-existing chronic immune stimulation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of extranodal MZL differs depending upon the tissue involved. The stomach is the most frequent site of involvement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MALT lymphoma may be related to chronic immune stimulation, due to bacterial or autoimmune stimuli. Patients with MALT may also display evidence of autoimmune disorders or infections with Helicobacter pylori, Borrelia afzelii, Chlamydophila psittaci, or Campylobacter jejuni. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of extranodal MZL is made based upon morphologic, immunophenotypic, and genetic analysis of biopsy material taken from an affected site. Morphologic review reveals a polymorphous infiltrate of small cells with reactive follicles. While large cells are typically present, they are by definition in the minority. On immunophenotype, cells are positive for B cell markers CD19, CD20, and CD22, and negative for CD5, CD10, and CD23. Chromosomal abnormalities, usually trisomy 3 or t(11;18), are found in most cases. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Morphology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Immunophenotype'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Genetic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of patients with extranodal (MALT) MZL includes other B cell lymphomas, most commonly diffuse large B cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, and follicular lymphoma. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Nodal MZL",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodal MZL is a primary nodal lymphoma with features identical to lymph nodes involved by extranodal (MALT) lymphoma, but without evidence of extranodal disease. It is rare, comprising approximately 1 percent of NHL cases. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients are asymptomatic, although most present with stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      non-bulky nodal disease. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Morphologically cases of nodal MZL can resemble extranodal (MALT) MZL or splenic MZL. Likewise, immunophenotype usually resembles extranodal (MALT) or splenic MZL in accordance with the morphologic features of the specific case. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Morphologic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Immunophenotypic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of nodal MZL is made based upon nodal biopsy evaluation in the context of the clinical presentation. This diagnosis should not be made in patients with extranodal (MALT) lymphoma at other sites, Sj&ouml;gren's syndrome, or when another low-grade B cell lymphoma (follicular lymphoma, mantle cell lymphoma) is present in the same node. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prognostic factors determining outcome with nodal MZL are not well defined. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/4\">",
"      Isaacson PG. Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 1999; 36:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/5\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/6\">",
"      Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992; 102:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/7\">",
"      Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/8\">",
"      Cogliatti SB, Schmid U, Schumacher U, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 1991; 101:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/9\">",
"      White WL, Ferry JA, Harris NL, Grove AS Jr. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology 1995; 102:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/10\">",
"      Rosado MF, Byrne GE Jr, Ding F, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood 2006; 107:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/11\">",
"      Koss MN. Pulmonary lymphoid disorders. Semin Diagn Pathol 1995; 12:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/12\">",
"      Borie R, Wislez M, Thabut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J 2009; 34:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/13\">",
"      Zukerberg LR, Medeiros LJ, Ferry JA, Harris NL. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol 1993; 100:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/14\">",
"      Wenzel C, Fiebiger W, Dieckmann K, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer 2003; 97:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/15\">",
"      Luminari S, Cesaretti M, Marcheselli L, et al. Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas. Ann Oncol 2010; 21:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/16\">",
"      Capelle LG, de Vries AC, Looman CW, et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/17\">",
"      Novak U, Basso K, Pasqualucci L, et al. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. Br J Haematol 2011; 155:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/18\">",
"      Ruland J, Duncan GS, Elia A, et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 2001; 104:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/19\">",
"      Ruefli-Brasse AA, French DM, Dixit VM. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003; 302:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/20\">",
"      Ruland J, Duncan GS, Wakeham A, Mak TW. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003; 19:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/21\">",
"      Ho L, Davis RE, Conne B, et al. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 2005; 105:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/22\">",
"      Hu S, Du MQ, Park SM, et al. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. J Clin Invest 2006; 116:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/23\">",
"      Bertoni F, Zucca E. Delving deeper into MALT lymphoma biology. J Clin Invest 2006; 116:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/24\">",
"      Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia 2007; 21:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/25\">",
"      Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/26\">",
"      Yonezumi M, Suzuki R, Suzuki H, et al. Detection of AP12-MALT1 chimaeric gene in extranodal and nodal marginal zone B-cell lymphoma by reverse transcription polymerase chain reaction (PCR) and genomic long and accurate PCR analyses. Br J Haematol 2001; 115:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/27\">",
"      Zhang Q, Siebert R, Yan M, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet 1999; 22:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/28\">",
"      Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/29\">",
"      Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/30\">",
"      Wlodarska I, Veyt E, De Paepe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/31\">",
"      Sagaert X, de Paepe P, Libbrecht L, et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006; 24:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/32\">",
"      Traweek ST, Sheibani K, Winberg CD, et al. Monocytoid B-cell lymphoma: its evolution and relationship to other low-grade B-cell neoplasms. Blood 1989; 73:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/33\">",
"      Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/34\">",
"      Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/35\">",
"      Iwamoto FM, DeAngelis LM, Abrey LE. Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology 2006; 66:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/36\">",
"      Tu PH, Giannini C, Judkins AR, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 2005; 23:5718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/37\">",
"      George AC, Ozsahin M, Janzer R, et al. Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature. Bull Cancer 2005; 92:E51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/38\">",
"      Welsh JS, Howard A, Hong HY, et al. Synchronous bilateral breast mucosa-associated lymphoid tissue lymphomas addressed with primary radiation therapy. Am J Clin Oncol 2006; 29:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/39\">",
"      Ikeda J, Morii E, Yamauchi A, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type developing in gonarthritis deformans. J Clin Oncol 2007; 25:4310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/40\">",
"      Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol 2002; 147:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/41\">",
"      Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol 2007; 31:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/42\">",
"      Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood 2009; 114:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/43\">",
"      Troch M, Formanek M, Streubel B, et al. Clinicopathological aspects of mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland: a retrospective single-center analysis of 28 cases. Head Neck 2011; 33:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/44\">",
"      Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/45\">",
"      Dabaja BS, Ha CS, Wilder RB, et al. Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer J 2003; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/46\">",
"      Liao Z, Ha CS, McLaughlin P, et al. Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. Int J Radiat Oncol Biol Phys 2000; 48:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/47\">",
"      Raderer M, W&ouml;hrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/48\">",
"      W&ouml;hrer S, Streubel B, Bartsch R, et al. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res 2004; 10:7179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/49\">",
"      Asatiani E, Cohen P, Ozdemirli M, et al. Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol 2004; 77:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/50\">",
"      Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol 2004; 126:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/51\">",
"      Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sj&ouml;gren's syndrome and hepatitis C virus infection. Arthritis Rheum 2007; 57:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/52\">",
"      Libra M, Gloghini A, Malaponte G, et al. Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol 2008; 49:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/53\">",
"      Isaacson PG. Gastrointestinal lymphoma. Hum Pathol 1994; 25:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/54\">",
"      Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/55\">",
"      Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/56\">",
"      Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/57\">",
"      Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997; 26:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/58\">",
"      Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000; 24:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/59\">",
"      Goodlad JR, Davidson MM, Hollowood K, et al. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 2000; 37:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/60\">",
"      Sch&ouml;llkopf C, Melbye M, Munksgaard L, et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood 2008; 111:5524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/61\">",
"      Husain A, Roberts D, Pro B, et al. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 2007; 110:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/62\">",
"      Ferreri AJ, Dolcetti R, Dognini GP, et al. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study. Int J Cancer 2008; 123:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/63\">",
"      Chanudet E, Adam P, Nicholson AG, et al. Chlamydiae and Mycoplasma infections in pulmonary MALT lymphoma. Br J Cancer 2007; 97:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/64\">",
"      Matthews JM, Moreno LI, Dennis J, et al. Ocular Adnexal Lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis. Br J Haematol 2008; 142:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/65\">",
"      Ponzoni M, Ferreri AJ, Guidoboni M, et al. Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods. Clin Cancer Res 2008; 14:5794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/66\">",
"      Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005; 23:5067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/67\">",
"      Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006; 98:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/68\">",
"      Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 2010; 150:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/69\">",
"      Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012; 30:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/70\">",
"      Vargas RL, Fallone E, Felgar RE, et al. Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience. Leuk Res 2006; 30:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/71\">",
"      Daibata M, Nemoto Y, Togitani K, et al. Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients. Br J Haematol 2006; 132:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/72\">",
"      Zucca E, Bertoni F. Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? J Natl Cancer Inst 2006; 98:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/73\">",
"      Gracia E, Froesch P, Mazzucchelli L, et al. Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. Leuk Lymphoma 2007; 48:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/74\">",
"      Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005; 105:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/75\">",
"      Ben-Ayed F, Halphen M, Najjar T, et al. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer 1989; 63:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/76\">",
"      Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/77\">",
"      Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology 1987; 11:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/78\">",
"      Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/79\">",
"      Schmid C, Kirkham N, Diss T, Isaacson PG. Splenic marginal zone cell lymphoma. Am J Surg Pathol 1992; 16:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/80\">",
"      Du M, Diss TC, Xu C, et al. Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. Leukemia 1996; 10:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/81\">",
"      Qin Y, Greiner A, Trunk MJ, et al. Somatic hypermutation in low-grade mucosa-associated lymphoid tissue-type B-cell lymphoma. Blood 1995; 86:3528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/82\">",
"      Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood 1997; 89:3335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/83\">",
"      Pan L, Diss TC, Cunningham D, Isaacson PG. The bcl-2 gene in primary B cell lymphoma of mucosa-associated lymphoid tissue (MALT). Am J Pathol 1989; 135:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/84\">",
"      Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood 1995; 85:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/85\">",
"      Ott G, Katzenberger T, Greiner A, et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997; 57:3944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/86\">",
"      Auer IA, Gascoyne RD, Connors JM, et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol 1997; 8:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/87\">",
"      Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 2011; 117:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/88\">",
"      Panayiotidis P, Kotsi P. Genetics of small lymphocyte disorders. Semin Hematol 1999; 36:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/89\">",
"      Mateo M, Mollejo M, Villuendas R, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999; 154:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/90\">",
"      Troussard X, Mauvieux L, Radford-Weiss I, et al. Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Fran&ccedil;ais d'H&eacute;matologie Cellulaire (GFHC) study. Br J Haematol 1998; 101:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/91\">",
"      Streubel B, Lamprecht A, Dierlamm J, et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/92\">",
"      Dierlamm J, Baens M, Stefanova-Ouzounova M, et al. Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes. Blood 2000; 96:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/93\">",
"      Schreuder MI, Hoeve MA, Hebeda KM, et al. Mutual exclusion of t(11;18)(q21;q21) and numerical chromosomal aberrations in the development of different types of primary gastric lymphomas. Br J Haematol 2003; 123:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/94\">",
"      Du MQ, Peng H, Liu H, et al. BCL10 gene mutation in lymphoma. Blood 2000; 95:3885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/95\">",
"      Alpen B, Neubauer A, Dierlamm J, et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood 2000; 95:4014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/96\">",
"      Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/97\">",
"      Liu H, Ye H, Dogan A, et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/98\">",
"      Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002; 99:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/99\">",
"      Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002; 3:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/100\">",
"      Taji S, Nomura K, Matsumoto Y, et al. Trisomy 3 may predict a poor response of gastric MALT lymphoma to Helicobacter pylori eradication therapy. World J Gastroenterol 2005; 11:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/101\">",
"      Liu H, Ye H, Ruskone-Fourmestraux A, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/102\">",
"      L&eacute;vy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005; 23:5061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/103\">",
"      Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003; 101:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/104\">",
"      Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/105\">",
"      Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/106\">",
"      Barth TF, D&ouml;hner H, Werner CA, et al. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood 1998; 91:4321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/107\">",
"      Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001; 98:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/108\">",
"      A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/109\">",
"      Carbone A, Gloghini A, Pinto A, et al. Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. Am J Clin Pathol 1989; 92:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/110\">",
"      Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol 2007; 136:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/111\">",
"      Campo E, Miquel R, Krenacs L, et al. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol 1999; 23:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/112\">",
"      Nizze H, Cogliatti SB, von Schilling C, et al. Monocytoid B-cell lymphoma: morphological variants and relationship to low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue. Histopathology 1991; 18:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/113\">",
"      Ngan BY, Warnke RA, Wilson M, et al. Monocytoid B-cell lymphoma: a study of 36 cases. Hum Pathol 1991; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/114\">",
"      Shin SS, Sheibani K, Fishleder A, et al. Monocytoid B-cell lymphoma in patients with Sj&ouml;gren's syndrome: a clinicopathologic study of 13 patients. Hum Pathol 1991; 22:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/115\">",
"      Nathwani BN, Anderson JR, Armitage JO, et al. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project. Hum Pathol 1999; 30:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/116\">",
"      Nathwani BN, Drachenberg MR, Hernandez AM, et al. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma). Semin Hematol 1999; 36:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/117\">",
"      Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999; 17:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/118\">",
"      Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology 2006; 48:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/119\">",
"      Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003; 27:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/9/19610/abstract/120\">",
"      Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer 2013; 119:99.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4733 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19610=[""].join("\n");
var outline_f19_9_19610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060690\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTRANODAL (MALT) MZL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Autoimmune disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Borrelia afzelii",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chlamydophila (Chlamydia) psittaci",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Campylobacter jejuni",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Immunoglobulin gene rearrangement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chromosomal abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      NODAL MZL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Morphologic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Immunophenotypic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Extranodal (MALT) MZL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Nodal MZL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4733\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4733|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/41/31376\" title=\"picture 1\">",
"      Gastric MALT lymphoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/12/9422\" title=\"picture 2\">",
"      Ulcerated MALT lymphoma Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/1/22552\" title=\"picture 3\">",
"      Gastric MALToma Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/62/15335\" title=\"picture 4\">",
"      Gastric MALToma B cell stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4733|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/39/35453\" title=\"table 1\">",
"      Presenting features NHL types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/25/39323\" title=\"table 2\">",
"      Grading GI MALT lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=related_link\">",
"      Clinical manifestations of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/28/18887?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/29/41431?source=related_link\">",
"      Epidemiology of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=related_link\">",
"      Primary cutaneous marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12470?source=related_link\">",
"      The heavy chain diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22169?source=related_link\">",
"      Treatment of marginal zone (MALT) lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_9_19611="First-rank symptoms in schizophrenia";
var content_f19_9_19611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F76914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F76914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    First-rank symptoms in schizophrenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Audible thoughts - hearing one's thoughts spoken aloud",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Somatic passivity - the feeling of being touched or strange unexplained sexual sensations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Thought insertion - the feeling an external force is putting thoughts into one's mind",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Thought withdrawal - thoughts are withdrawn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Thought broadcasting - the feeling people can read one's mind",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Made feelings - the feeling an external force is making you experience something",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Made impulses - the feeling an external force is making you want something",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Made volition - the feeling an external force is making you act a certain way",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Voices arguing/discussing (often referring to the patient as \"he\" or \"she\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Voices commenting - voices narrate one's actions as if giving a running commentary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Delusional percepts - a physical sensation (such as seeing or feeling something) that is interpreted as a very special event has happened and something important is realized",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19611=[""].join("\n");
var outline_f19_9_19611=null;
var title_f19_9_19612="Verification level";
var content_f19_9_19612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trauma center verification level: setting and capability for children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Verification level",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Capability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Pediatric trauma center (PTC)",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         Freestanding children's hospital or university hospital with equivalent pediatric services",
"        </p>",
"        <p>",
"         Tertiary care center",
"        </p>",
"       </td>",
"       <td>",
"        24 hour comprehensive management of a high volume of critically ill children with an immediately available operating room",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Management by pediatric surgeons and pediatric medical subspecialists*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ancillary pediatric support services (eg, child life, respiratory therapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediatric ED, ICU, acute care unit, and rehabilitation services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administrative support to manage all components of a pediatric trauma program, including performance improvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ongoing pediatric trauma research and education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Adult trauma center with added qualification in pediatrics (ATC AQ)",
"       </td>",
"       <td rowspan=\"4\">",
"        General tertiary care hospital or adult university hospital",
"       </td>",
"       <td>",
"        24 hour comprehensive management of critically ill children with an immediately available operating room but at a lower volume than PTC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma surgeons credentialed for pediatric trauma care but not necessarily pediatric surgeons. No pediatric medical subspecialty requirement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fully equipped Pediatric ED and ICU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediatric performance improvement program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult trauma center, Level I (ATC)",
"       </td>",
"       <td>",
"        General tertiary care hospital",
"       </td>",
"       <td>",
"        No specific pediatric capability required but typically fully equipped for resuscitation of a critically injured child",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ED: emergency department; ICU: intensive care unit.",
"     <br>",
"      * Pediatric medical subspecialists include pediatric emergency medicine, critical care, and anesthesia. Other surgical subspecialists must have pediatric specialty expertise.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reference: Committee on Trauma. Resources for optimal care of the injured patient 2006. American College of Surgeons , Chicago, 2006, p. 55.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19612=[""].join("\n");
var outline_f19_9_19612=null;
var title_f19_9_19613="Causes of abdominal pain by location";
var content_f19_9_19613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of abdominal pain by location",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Right upper quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholecystitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholangitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Biliary colic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Budd-Chiari syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumonia/empyema pleurisy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Subdiaphragmatic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Right lower quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salpingitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ectopic pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inguinal hernia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nephrolithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesenteric adenitis (yersina)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Epigastric",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peptic ulcer disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroesophageal reflux disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myocardial infarction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pericarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ruptured aortic aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Periumbilical",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Early appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bowel obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ruptured aortic aneurysm",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Left upper quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Splenic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Splenic infarct",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastric ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Left lower quadrant",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diverticulitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salpingitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ectopic pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inguinal hernia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nephrolithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Irritable bowel syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Diffuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesenteric ischemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metabolic (eg, DKA, porphyria)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial Mediterranean fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bowel obstruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peritonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Irritable bowel syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19613=[""].join("\n");
var outline_f19_9_19613=null;
var title_f19_9_19614="Orbital floor fracture";
var content_f19_9_19614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Orbital floor fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a fracture in the floor of the left orbit with a large fragment of bone (white arrow) in the maxillary sinus. The left maxillary sinus is filled with blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard G Bachur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19614=[""].join("\n");
var outline_f19_9_19614=null;
var title_f19_9_19615="Chromosomal transloc Ewing FISH";
var content_f19_9_19615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical chromosomal translocation seen in Ewing sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorescence in situ hybridization (FISH) study demonstrating the (11;22)(q24;q12) translocation [der(22)] found in Ewing sarcoma and primitive peripheral neuroectodermal tumors (PNET).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew L Rosenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_9_19615=[""].join("\n");
var outline_f19_9_19615=null;
